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ABSTRACT
The sarco/endoplasmic reticulum calcium ATPase (SERCA) and its inhibitor
phospholamban (PLB) are major regulators of Ca2+ levels in the cardiac cell. Deficient
calcium handling in the heart has been linked to heart disease, including heart failure; the
leading cause of death in developed countries. As of today, targeting SERCA and SERCA-PLB
complex to enhance cardiac function has not been successful due to lack of details on the
SERCA regulatory mechanisms. Previous molecular dynamics (MD) simulations by my lab
predicted that a small loop in SERCA N-domain (Nβ5-β6 loop) regulates SERCA transition
from open-to-closed conformation and may interact with PLB cytosolic domain. Thus, I
hypothesized that the Nβ5-β6 loop plays a role in (1) SERCA structural dynamics during
Ca2+ transport and (2) SERCA regulation via interaction with PLB cytosolic domain.
Two-color SERCA (2CS) labeled with fluorescent proteins on two of the headpiece
domains was used in FRET measurements, and open SERCA conformers were detected
during transient Ca2+ elevations. I believe these open conformers represent a steady-state
population of SERCA in the sloe step of the Ca2+ cycle. In the presence of sustained Ca2+
elevation the wild-type SERCA, but not the mutated transporter, acquired a new slow step
and accumulated in non-physiological high-Ca2+ affinity closed conformation. Measurement
of SERCA function in vitro showed that the mutated transporter still hydrolyzed ATP and
have normal Ca2+ affinity, but maximal ATPase activity was reduced by
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63%. I attribute this functional deficit to the decrease in SERCA headpiece compact
assembly as was detected in silico and in live cells.
2CS FRET quantifications in microsomes detected ligand-stabilized compact
conformers for high-affinity (E1) transporter, while low-affinity (E2) states were
characterized by more open conformations. Additional MD simulations have shown steady
interactions of Nβ5-β6 loop with PLB cytoplasmic domain irrespective of loop mutations or
PLB phosphorylation status. SERCA ligand-stabilized conformers detected with FRET
obtained more closed structure in the presence of PLB, and extra compact assembly upon
PLB Ser16 phosphorylation. Overall, these data reveal a discrete structural element that
facilitates a compact conformation during Ca2+ transport and enhanced scientific
understanding of ATPase transporters function and regulation.
Additionally, I utilized 2CS FRET biosensor to confirm long-time predicted direct
interaction with the indirect SERCA regulator HAX-1 and to study the association with the
recently identified regulatory micropeptide DWORF. Even more, my lab applied 2CS
labeling technique to generate another 2-color ATPase transporter biosensor, 2-color MRP1, which was used in FRET high-throughput screening to identify novel MRP-1 substrates. I
further determined functional effect of identified ligands on MRP-1 function in live cells
and confirmed the 2-color labeling technique to be useful for generation of FRET
biosensors in drug discovery.
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CHAPTER ONE
INTRODUCTION AND BACKGROUND
The Cardiac Calcium ATPase in the Heart
Calcium (Ca2+) serves as a signaling molecule in the heart to drive muscle contraction, thus
removal of Ca2+ from the sarcoplasm is essential for myocardium relaxation (Bers, 2002).
In particular, Ca2+ binding to a Ca2+ sensor Troponin C induces conformational changes in
myofilament arrangement, which results in contraction. Sarco-endoplasmic reticulum
calcium ATPase (SERCA) transports Ca2+ from the cytosol into the endoplasmic/
sarcoplasmic reticulum (ER/SR) lumen and in this way regulates relaxation of the heart.
Sequestering Ca2+ from the cytosol by SERCA also affects contractile force, as restored SR
Ca2+ load determines the force of the myofilament contractions. Figure 1 shows the Ca2+induced myofilament contraction/relaxation cycle in cardiac myocyte (Fig. 1A) and
changes in cytosolic Ca2+ during this cycle (Fig. 1B). Depolarization across the transverse
tubule membrane opens L-type calcium channels, causing an influx of Ca2+ into sarcoplasm
(1). The influx of Ca2+ induces Ca2+ release from the SR lumen through ryanodine receptors
(RyR) into sarcoplasm, where Ca2+ binds to myofilament force-generating structures and
induces contraction (2). Relaxation (3) is produced when Ca2+ is removed from the
sarcoplasm primarily through SERCA (approximately 70% of Ca2+ removal (Bassani et al.,
1994)) and calcium transporters on the plasma membrane (not shown). During influx of

1

2

Figure 1. Schematic representation of calcium handling in the cardiac myocyte.
(A) Depolarization across the transverse tubule membrane opens L-type calcium channels,
causing an influx of Ca2+ into sarcoplasm (1). The influx of Ca2+ induces Ca2+ release from
the SR lumen through RyR into sarcoplasm, where Ca2+ binds to myofilament and induces
contraction (2). Relaxation (3) is produced when Ca2+ is removed from the sarcoplasm
through primarily SERCA into SR lumen. SERCA can be inhibited by PLB.
(B) Trace represents cytosolic Ca2+ change over time in response to Ca2+-induced Ca2+ release from ER through RyR opening. (1-3) correspond to events in (A).
sarcoplasmic Ca2+ (Fig. 1, (2)), SERCA is active and continuously undergoes structural
changes in order to progress throughout the enzymatic cycle presented in Fig. 3.
Previous studies have shown that SERCA function is reduced in heart failure (HF)
(Gwathmey et al., 1987; Roe et al., 2015). HF is defined as the inability of the heart to keep
up with its workload. Normally, the heart provides adequate blood flow to supply oxygen
and nutrients to the cells and remove carbon dioxide and metabolites. In HF, the body may
not get the oxygen it needs. HF is a chronic and progressive condition and a major cause of
morbidity and mortality worldwide (Mosterd and Hoes, 2007; Mozaffarian et al., 2016).
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While patients are treated with medications, lifestyle changes, surgical procedures and
device implantation (Yancy et al., 2017), there is no cure for HF available.
HF has been linked to deficient Ca2+ handling in failing cardiac cells (Bers, 2006).
More specifically, in humans failing myocardium SR Ca2+ load is decreased (Lindner et al.,
1998; Piacentino et al., 2003; Pieske et al., 1999), while cytosolic calcium levels remain
elevated during the relaxation period (Beuckelmann et al., 1992; Gwathmey et al., 1991). As
a result, the failing heart has weak muscle contraction and reduced cardiac output. Since
SERCA is a primary regulator of calcium handling in myocardium, it is an appealing target
to treat cardiac diseases. In particular, increasing SERCA activity in failing cardiac cells is
predicted to improve heart function (Hayward et al., 2015; Inesi et al., 2008). Recently,
phase 2 of gene therapy clinical trials aimed at upregulation of SERCA, the most promising
heart failure treatment option (Horowitz et al., 2011), had failed to significantly improve
patient’s cardiac function (Zsebo et al., 2014). This study was aimed at increasing SERCA
levels in heart failure patients by the adeno-associated viral expression. At the dose tested,
increased SERCA levels did not improve the clinical outcome of heart failure patients
(Greenberg et al., 2016). One possible explanation is that simply increasing SERCA levels is
not sufficient to overcome heart failure symptoms. Instead, enhancing SERCA function is an
alternative approach for the discovery of novel therapeutic options. The present study was
aimed to add to understanding of SERCA function by investigation of SERCA structural
dynamics during Ca2+ transport.
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SERCA in Other Diseases
Besides being a key component in heart failure manifestation, various SERCA isoforms have
been implicated in other pathologies. Recently SERCA has been implicated in cancer stemlike cell survival by preventing Ca2+-induced apoptosis in glucose-deprived conditions due
to sequestering Ca2+ from cytosol (Park et al., 2017). Other reports emphasize SERCA
importance in skin health, where somatic mutations in SERCA2b lead to Darier’s disease,
characterized by epidermal lesions (Savignac et al., 2011; Takagi et al., 2016). This disorder
results from a tissue-specific missense, non-sense, frameshift, and splicing mutations,
which affect both SERCA2b and SERCA2a. Being a major isoform expressed in the
epidermis, loss-of-function SERCA2b mutation has a detrimental effect on the health of the
epidermis with variety of clinical manifestations.
Germline mutations of skeletal SERCA1a isoform result in pathological skeletal
muscle stiffness, called Brody myopathy (Odermatt et al., 1996), while overexpression of
SERCA2a rescues dystrophic phenotype in mice (Goonasekera et al., 2011). Based on the
variety of SERCA function in all of these disorders, SERCA is a high value therapeutic target.
Nevertheless, the details of SERCA structural dynamics during Ca2+ cycle are still not
resolved to the degree that would allow targeted transporter regulation. This study was
aimed at discovering the detail of SERCA structural dynamics during Ca2+ cycle.
SERCA Structure and Function
SERCA is the ion transporter that is responsible for sequestration of calcium Ca2+ in the
ER/SR. There are three isoforms of SERCA: SERCA1-3 encoded by ATP2A1-3 respectively.
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Figure 2. SERCA structure.
SERCA structure showing the actuator (A) in blue, nucleotide-binding (N) in yellow, autophosphorylation (P) in black, transmembrane (TM) domains in grey, The Nβ5-β6 loop is
highlighted in orange, and three acidic residues Asp426, Glu429, and Glu435 are labeled in
magnified insert.
Sarcoplasmic reticulum ATPase SERCA2 belongs to a Ca2+ P-type ATPase2 family which has
two isoforms: SERCA2a and SERCA2b resulting from alternative splicing of the exon 20 and
only differ in their C-terminus (SERCA2b has an additional transmembrane helix 11).
SERCA2a is expressed in cardiac myocytes and slow-twitch skeletal muscles. SERCA2b is
expressed in almost all tissues. SERCA2 isoforms are found in ER/SR and involved in the
Ca2+ transport from the cytoplasm/sarcoplasm to the lumen of ER/SR (Periasamy and
Kalyanasundaram, 2007). Orthologues of SERCA2 pumps are common in bacteria and most
likely human SERCA2 transporters evolved as a mechanism to transport Ca2+ against a
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steep gradient (Deves and Brodie, 1981). The main focus of the current study is on the
cardiac isoform SERCA2a.
The first SERCA to have the crystal structure determined was SERCA1a of rabbit
muscle (Toyoshima et al., 2000). Today, there is an abundant collection of SERCA
structures in the PDB database, including conformers in various ligand-stabilized states.
Based on these data, a clear picture of SERCA structure emerged. As illustrated in Fig. 2,
SERCA2a contains four distinct domains: three cytoplasmic domains (A, actuator; N,
nucleotide binding; P, phosphorylation) comprise a cytoplasmic headpiece, while 10-helical
transmembrane (TM) domain transports Ca2+ (Toyoshima, 2008). Each of the domains has
its unique function. The nucleotide binding N-domain (Fig. 2, yellow) has two main
functions: binding of ATP and phosphorylation of P-domain. The N-domain core structure
is conserved among SERCA isoforms and contains crucial residues (e.g. Phe487) for ATP
binding (Sorensen et al., 2004). In ATP bound state, the N-domain undergoes structural
rearrangements and becomes linked to P-domain via nucleotide-mediated interactions
which allows phosphorylation of P-domain to take place (Toyoshima, 2008).
The phosphorylation P-domain (Fig. 2, black) contains the phosphorylated residue
Asp351 placed in conserved Asp-Lys-Thr-Gly (DKTG) motif, and Mg2+-coordinating residue
Asp703 positioned in conserved Thr-Gly-Asp-Asn (TGDN) sequence (Aravind et al., 1998;
Picard et al., 2007). Besides being linked to the N-domain, P-domain’s flat surface allows
docking and rotation for A-domain (Toyoshima, 2009), thus potentially mediating A−Ndomains interaction.
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The actuator A-domain (Fig. 2, blue) has a conserved Thr-Gly-Glu-Ser (TGES) motif
(Moller et al., 1996) which plays an important role in dephosphorylation of P-domain
residue Asp351 (Clausen et al., 2004), thus serving a protein phosphatase function. Adomain connects to TM-domain via a long linker that allows A-domain to be flexible and
serve as a gating mechanism (actuator) for Ca2+ binding and release (Toyoshima et al.,
2007).
SERCA transports two Ca2+ ions from cytosol to the ER/SR lumen for every ATP
hydrolyzed (Inesi et al., 1980). In addition, SERCA counter-transports 2 or 3 H+ ions (Stokes
and Green, 2003; Yu et al., 1993). According to classical theory for ion transport, when Pdomain gets phosphorylated via ATP hydrolysis, the ATP-mediated interaction between Nand P-domains breaks, and P-domain shifts and pulls along the A-domain, which in turn
tugs the A-domain linker connected to TM-domain. These complex structural
rearrangements of cytoplasmic headpiece result in TM reorganization suitable for Ca2+
transport (Toyoshima, 2008).
There are two Ca2+ transport sites in the center of the TM-domain, which can be in
high or low affinity states, and sequential Ca2+ binding is cooperative (Inesi et al., 1980).
Ca2+ binding to the site I is maintained by oxygen side chains and one water molecule on
cytosolic side of helixes M5, M6, and M8. Only after the first Ca2+ binds, can the second Ca2+
bind to site II on nearby helix M4 which provides 3 main chain carbonyl groups for ion
coordination (Toyoshima et al., 2000). If Ca2+ binding sites are exposed to the cytoplasmic
site, then the ATPase is in a high-affinity (E1) conformation. On the other hand, if Ca2+
binding sites are exposed to the luminal side of ER membrane, the transporter is in a low-
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affinity state (E2) (Moller et al., 2010). Transition of the transporter from E1 to E2
conformation has been proposed to be induced by phosphorylation event. Specifically, Pdomain phosphorylation results in distortion of the high-affinity binding sites and opens an
ion exiting channel on the other side of the membrane, while repositioning the
dephosphorylation TGES motif of A-domain closer to the phosphorylation site on P-domain
(Moller et al., 2010; Toyoshima and Mizutani, 2004). The consequent repositioning of Adomain during hydrolysis of aspartylphosphate of P-domain (dephosphorylation event)
results in transition of the pump from the E1 to E2 conformation, which is predicted to be
the slowest step of the Ca2+ catalytic cycle (Fig. 2, (c)) (Champeil et al., 1986; Hanel and
Jencks, 1990; Petithory and Jencks, 1986). Fig. 3 presents a simplified schematic overview
of SERCA Ca2+ transport cycle steps, including Ca2+ binding (a), phosphorylation (b), Ca2+
release (c), dephosphorylation (d), and reset of cycle by ATP binding (e). All of these steps
of the enzymatic cycle are intrinsically regulated by means of the transporter structural
determinants’ responses to the ligand (Ca2+, ATP, Mg2+) binding and their or their
metabolites release events. For example, SERCA structural rearrangement during
transition from open to close conformation upon Ca2+ binding (Toyoshima and Mizutani,
2004) was proposed to result in the restriction of ATP delivery to phosphorylation site, and
thus prevent the sequence of events that would lead to TM-domain rearrangement and
backflow of Ca2+ ions from the SR luminal side (Toyoshima, 2008; Toyoshima, 2009). This
idea of internal structural determinants regulating the pump catalytic cycle is a powerful
approach to understanding SERCA functional mechanisms. Identification of the structural
determinants that regulate SERCA catalytic cycle would be beneficial in rational design of
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Figure 3. Simplified schematic overview of SERCA kinetic cycle.
E1 state are yellow and E2 states are green. (a) ATP binding induces conformational
changes that facilitate Ca2+ binding at the cytosolic membrane side. (b) P-domain phosphorylation and ATP hydrolysis. (c) Ca2+ release at the other side of membrane. (d)
Dephosphorylation. (e) ATP binding. Steps (c-d) are predicted to be the slowest.
SERCA targeted modulators. Up to this point, only few SERCA specific activators have been
identified, and their potency is still under investigation (Cornea et al., 2013; Dahl, 2017;
Kang et al., 2016). One of the goals of this work was to contribute to understanding of
SERCA function via thorough investigation of SERCA structural dynamics during Ca2+
transport.
Nβ5-β6 Loop is Predicted to Regulate SERCA Compact Conformation
The advances in crystallography and electron microscopy techniques allowed science to
capture SERCA short-lived transitional structures in biochemically-stabilized
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environments. Nevertheless, the structural dynamics of SERCA during Ca2+ cycling have not
been fully discovered and alternative approaches are needed to investigate transitional
conformations. A recent computational study by Smolin et al. (Smolin and Robia, 2015a)
has identified a β-loop in SERCA N-domain as a potential regulator of SERCA transition
from open-to-closed conformation. This short (10 amino acids) Nβ5-β6 loop has three
negatively charged residues (Asp426, Glu429, and Glu435) which are predicted to interact
with positive cluster on the A-domain surface. Formation of H-bonds/salt bridges between
the Nβ5-β6 loop and polar/basic residues of A-domain is predicted to penetrate the poorly
diffusible water cushion separating A- and N-domains and facilitate the closure of the
SERCA cytoplasmic headpiece during Ca2+ transport cycle. The N-domain Nβ5-β6 loop is
highly conserved among SERCA isoforms and multiple species (Smolin and Robia, 2015a).
Analysis of two major human genome variance databases (OMIM and COSMIC) revealed
that Nβ5-β6 loop carries no reported mutations (Amberger et al., 2015; Forbes et al., 2015).
High preservation and absence of variance in this discrete structure suggest that SERCA
Nβ5-β6 loop residues may play an important role in transporter assembly/function. One of
the goals of the current study is to investigate in detail the predicted role of Nβ5-β6 loop in
SERCA structural regulation and function.
SERCA Regulation by PLB
The SERCA’s main inhibitor is phospholamban (PLB), a 52-amino-acid residue polypeptide
(Fig. 1, PLB in red) (Kirchberber et al., 1975; Tada and Inui, 1983; Toyoshima et al., 2003).
PLB is composed of amino-terminal cytosolic α-helix, connected via an unstructured hinge
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to a carboxyl hydrophobic transmembrane single-spin α-helix (Simmerman et al., 1986).
PLB binds to SERCA at the TM groove composed of helixes M2 (residues 89-119), M4
(residues 313-330), M6 (residues 789-809), and M9 (residues 932-950) and stabilizes
SERCA conformation in reduced affinity for Ca2+, and thus reduces maximal Ca2+ transport
rate (Vmax) (Chen et al., 2006; Morita et al., 2008). SERCA inhibition by PLB is relieved when
PLB cytosolic domain is phosphorylated by protein kinase A (PKA) on Ser16 or
calcium/calmodium-dependent protein kinase II (CaMKII) on Thr17 (Simmerman et al.,
1986; Tada and Inui, 1983). Several studies suggest that PLB phosphorylation increases
SERCA maximal rate of Ca2+ transport beyond of SERCA Vmax alone (Antipenko et al., 1997;
Reddy et al., 2003), suggesting that PLB binding even ‘primes’ SERCA for more efficient
enzymatic cycling.
In the SR membrane PLB forms homo-pentamers, and upon de-oligomerization into
active monomers is able to bind and inhibit SERCA (Simmerman and Jones, 1998). PLB
mutations that prevent homo-pentamer formation and thus enhance a monomeric form of
PLB have been shown to improve PLB ability to inhibit SERCA (Kimura et al., 1997). It is
assumed that PLB monomers bind to SERCA, while PLB homo-pentamers serve as a noninhibitory reserve pool (Simmerman and Jones, 1998). PLB monomeric to pentameric
equilibrium is highly dynamic (Robia et al., 2007) with different affinities of PLB monomers
to different SERCA conformational states (Bidwell et al., 2011). The interaction between
PLB subunits and SERCA conformers are still under investigation.
Currently, there are two models how PLB phosphorylation causes relief of SERCA
inhibition. The dissociation model suggests that PLB phosphorylation results in PLB
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dissociation from SERCA, which allows SERCA to return into a high Ca2+ affinity
conformational state (Chen et al., 2006; James et al., 1989; Kimura et al., 1997).
Nevertheless, this model does not explain why phosphorylation of PLB results in SERCA
maximal rate of Ca2+ transport increase beyond Vmax of SERCA alone (Antipenko et al.,
1997; Reddy et al., 2003). The alternative model, the so called ‘subunit’ model, predicts that
PLB remains bound to SERCA after phosphorylation (Bidwell et al., 2011; Negash et al.,
2000). This model predicts that PLB binding serves as a SERCA “shortcut” to efficient Ca2+
transport by shifting ATPase conformation to an ordered, compact and high Ca2+ affinity
(high-efficiency) structural state (Pallikkuth et al., 2013). Additionally, the significant
structural changes in SERCA-PLB complex toward more compact conformation upon PLB
phosphorylation have been supported by the decrease in SERCA-to PLB FRET (Hou et al.,
2008). Thus, this model of PLB shift becomes more and more predominant over
dissociation model.
Unfortunately, the crystal structure of SERCA-PLB regulatory complex has been
determined without the PLB cytosolic domain (residues 1-23 not resolved) due to its highly
dynamic structure (Akin et al., 2013). To date, it remains unclear how PLB cytosolic domain
phosphorylation can induce SERCA-PLB compact conformation and increased Ca2+
transport rate. My lab’s recent MD simulations of SERCA spontaneous motions have shown
that SERCA Nβ5-β6 loop was in position to interact with PLB cytosolic domain (Smolin and
Robia, 2015a); thus, it is reasonable to hypothesize that Nβ5-β6 loop could be an intrinsic
regulator of SERCA function via interaction with PLB. Specifically, Nβ5-β6 loop has three
negatively charged residues, Asp426, Glu429, and Glu435, which are potential candidates
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for interaction with multiple positive residues on PLB cytosolic domain. Negative charges
introduced to Ser16 and Thr17 with addition of phosphoryl groups upon phosphorylation
may cause repulsion of PLB cytosolic domain from negative loop residues and in this way
become that force that shifts SERCA-PLB complex and relieves it from inhibition. One of the
goals of current study is to examine the regulatory complex in more detail and investigate
the possible role of Nβ5-β6 loop in structural regulations in SERCA-PLB regulatory
complex.
SERCA in Regulatory Complexes: HAX-1 and DWORF
SERCA regulation is a plausible target to improve cardiac function in heart related
disorders. Even though PLB remains a major SERCA regulator, recently other molecules
were predicted to regulate pump activity. Two of them, HAX-1 and DWORF, were included
in the scope of current study and are described below.
HS-1-Associated-protein-X-1 (HAX-1) is a ubiquitously expressed protein that has
been shown to play an anti-apoptotic role in striated muscles via interaction with the
mitochondrial enzyme caspase-9 (Han et al., 2006). In failing heart, Hax-1 has been shown
to interact with SERCA inhibitor phospholamban residues 16-22, which overlaps with
phosphorylation sites (Vafiadaki et al., 2007). The HAX-1 pull-down experiments detected
SERCA in complex with HAX-1 and PLB, which suggests that PLB can interact with both
HAX-1 and SERCA simultaneously, or alternatively, HAX-1 can interact with both SERCA
and PLB at the same time (Kimura and Inui, 2002). HAX-1 binding to SERCA has been
confined to residues 575-594 on N-domain by additional in vitro pull-down experiment
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(Vafiadaki et al., 2009). Recently, Hax-1 has been reported to promote cell survival via
positive regulation of SERCA levels (Bidwell et al., 2017; Vafiadaki et al., 2009) and mediate
PLB inhibitory activity on SERCA (Bidwell et al., 2018), which suggests that SERCA is under
HAX-1 regulation. Nevertheless, direct binding of HAX-1 to SERCA in live cells that is not
mediated by simultaneous association with PLB is still under investigation
(Vandecaetsbeek et al., 2011). I examined the direct effect of Hax-1 on SERCA headpiece
closure.
Long noncoding RNAs (lncRNA) were long viewed as junk nucleic acids that are not
translated into proteins. Nevertheless, over the last decade, lncRNAs have been
demonstrated to carry out transcriptional regulation, serve as scaffold, and to functionally
regulate proteins and RNA molecules (Ulitsky and Bartel, 2013). Even more strikingly,
some lncRNAs were identified as transcripts that encode short peptides (Anderson et al.,
2015; Matsumoto et al., 2017; Nelson et al., 2016). The Dworf RNA transcript encodes the
muscle-specific short peptide named DWORF (Nelson et al., 2016). DWORF has been shown
to localize in SR with SERCA and has been predicted to physically interact with SERCA at
the same groove and with similar affinity as PLB. Moreover, DWORF enhances SR Ca2+
uptake by SERCA through displacement of the inhibitory PLB, and is proposed to be a
promising therapeutic target to enhance cardiac contractility. I examined the detail of
DWORF interaction with and regulation of SERCA in this study, which is discussed further.
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2-color ATPase Transporters: SERCA and MRP-1
My laboratory developed a 2-color SERCA FRET biosensor for a high-throughput screening
strategy that allowed identification of molecule’s effectors with high precision and speed in
live cells. This technique is used for drug discovery and has a potential for rapid and
precise identification of small-molecule regulators of transporter activity (Cornea et al.,
2013). The transport ATPases include not only Ca2+ pumps like SERCA, but a wide variety
of proteins that move different types of ions or molecules across the biological membranes
(Pedersen, 2005). All ATPase transporters hydrolyze ATP in order to move substrates
across membranes and are involved in variety of physiological processes. Mutations
observed in ATPases result in a large number of diseases. While SERCA belongs to P-type
ATPase class, there are three more major classes: V, F, and ABC types.
Multidrug resistance protein 1 (MRP-1) is an ABC (ATP-binding cassette) family
plasma membrane transporter that exports a wide variety of drugs from the cell (Deeley et
al., 2006). As a result, MRP-1 is a major contributor to the failure of chemotherapy in
cancer patients. It is only recently a high resolution MRP-1 structure was resolved with
electron cryomicroscopy (Johnson and Chen, 2017), and before that, homologous ABCfamily transporters were used to predict MRP-1 structure. MRP-1 has been expected to be
composed of two membrane spanning domains and two cytoplasmic nucleotide-binding
domains (Dean and Allikmets, 2001). Two structural conformers of MRP-1 were predicted
to exist. The first one is a low substrate-affinity conformation with nucleotide-binding
domains locked together and ligand-binding site exposed to the extracellular environment
(Fig. 36A, bottom panel), while a second one is a high substrate-affinity conformation with
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binding site exposed to cytoplasm and nucleotide-binding domains separated (Fig. 36A, top
panel) (Aller et al., 2009). Without the MRP-1 structure resolved, the real conformational
dynamics of this important transporter were not defined, and an alternative approach was
needed to investigate the MRP-1 structural determinants. My lab used similar to 2CS
labeling strategy (Hou et al., 2012; Pallikkuth et al., 2013) in generating 2-color MRP-1
biosensor. Fluorescent MRP-1 sensor was used for identification of transporter’s structural
dynamics and to monitor the conformational changes of MRP-1 nucleotide binding
domains in the presence of small molecules. As a result, several substrates that induced
MRP-1 conformational changes were identified as candidates into MRP-1 allosteric
modulators (Iram et al., 2015). This study describes advanced investigation of functional
significance of identified compounds in MRP-1 activity as a part of present project.
Overall, this dissertation work concentrates on structural dynamics and regulation
of several ATPases, predominantly SERCA. Specifically, I investigate SERCA headpiece
structural transitions during the enzymatic cycle and a role of Nβ5-β6 loop during these
transitions. I examine SERCA’s regulatory interactions, mostly with PLB and in a smaller
scale with DWORF and HAX-1. In my investigations, I utilize FRET biosensor labeling
strategy to carry out SERCA structural measurements. I successfully apply this strategy to
generating MRP-1 FRET sensor and showed that this approach can be used as a wideranging tool in structural biology and drug discovery.

CHAPTER TWO
MATERIALS AND METHODS
Molecular Biology and Cell Culture
The engineering and functional characterization of 2CS has been previously described in
detail by Hou et al (Hou et al., 2012). I used a canine SERCA2a construct labeled with Cer on
the N-terminus and a YFP intra-sequence tag inserted before residue 509 in the N-domain.
In some experiments, like ATPase assay, I used an analogous construct, with Tag-RFP on
the N-terminus and an EGFP tag inserted before residue 509 in the N-domain. The Cer-YFP
pair has a Förster distance (R0) of 49.8 Å and the EGFP-TagRFP pair has an R0 of 58.3 Å
(Gadella, 2011). Ala mutations in Nβ5-β6 loop residues Asp426, Glu429, Glu435 were
introduced with QuickChange Lightning Site-Directed Mutagenesis Kit (Agilent
Technologies, Stratagine, La Jolla, CA) according to the manufacture’s protocol. Single
mutations and a triple mutation were made: Asp426Ala, Glu429Ala, Glu435Ala, and
Asp426Ala/Glu429Ala/Glu435Ala (AAA). Adenoviral vectors of TagRFP-EGFP-SERCA (WT
and AAA) were obtained from the Loyola Cardiovascular Research Institute virus
production facility. All constructs were validated with nucleotide sequencing and in
fluorescent signal in cell expression.
AAV-293 cells were cultured and transiently transfected using MBS mammalian
transfection kit (Agilent Technologies, Stratagine, La Jolla, CA) as described previously
(Hou et al., 2012). Briefly, the transfected cells were trypsinized for 1 min and plated onto
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Figure 4. Acceptor-sensitized FRET.
(A) AAV293 cells expressing Cer-YFP 2-color SERCA. (B) 2-color SERCA intramolecular
FRET was measured between donor and acceptor fluorophores attached to A- and N-domains respectively. As a control, thapsigargin (TG) addition results in SERCA population to
obtain open headpiece conformation (low FRET). The addition of Ca2+ activates and shifts
SERCA population to more compact, closed headpiece state (high FRET).

poly-D- and allowed to adhere for 1−2 hr prior to imaging.
Fluorescence Microscopy and FRET Quantification
Acceptor-sensitized emission FRET was used to measure intermolecular protein-protein or
intramolecular protein interactions. This technique allows excited-state energy to be
transferred directly from excited fluorophore (donor) to a proximate molecule (acceptor)
and thus provides evidence of molecule interactions (Day and Davidson, 2012; Gordon et
al., 1998). FRET was calculated from fluorescence intensities of donor (Cer) and acceptor
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(YFP) images, as well as an image that captures the acceptor emission with donor
excitation.
Wide-field fluorescent microscopy was done as described previously (Hou et al.,
2008). Briefly, cells expressing 2-color SERCA (Fig. 4A) were imaged with an inverted
microscope (Nikon Eclipse TE2000-U) equipped with a metal halide lamp and a backthinned CCD camera (iXon 887: Andor Technology, Belfast, Northern Ireland). For each
sample, acquisition of the field was performed with a 60×1.49 N.A. objective with 100 or
150−ms exposure for each channel: Cer, YFP, and FRET. Fluorescence intensity was
automatically quantified with a multiwavelength cell scoring application in MetaMorph
software (Molecular Devices, Sunnyvale, CA). The background threshold was set to 100
counts. Cell size criteria were limited to 30-80 μm diameter or manually defined by
drawing a cell contour. FRET efficiency E was calculated according to E=Fem/(Fem+G×FCer)
where Fem=FFRET−a×FYFP−d×FCer (Bidwell et al., 2011; Hou et al., 2008), FFRET, FYFP, and FCer
are the matching fluorescence intensity from FRET, YFP, and Cer images, respectively, and
G represents FRET intensity corrected for the bleed-through of the channels calculated as
in photobleaching-correction method described by Zal and Gascoigne (Zal and Gascoigne,
2004). G was calculated as
*+,(𝐹%& ) − )𝐹%&
.
𝐺=
𝐹/012 − 𝐹3%4
*+,-

where 𝐹%& calculated before and 𝐹%& calculated after photobleaching, and G determined to
be 3.20 for experimental set up. The acceptor photobleaching technique details are
descried below. The parameters a and d are bleed-through constants calculated as a=
FFRET/FCer for a control sample transfected with only YFP-SERCA, and d= FFRET/FCer for a

20

Figure 5. Acceptor photobleaching FRET.
(A) Representative images of AAV293 cells expressing PLB labeled with Cer and PLB labeled with YFP before and after photobleaching. PLB was used as control in photobleaching
experiments, as it is known to form dimers and pentamers. (B) Acceptor (YFP) fluorophore
intensity decreasing, while donor (CFP) fluorescence intensity is increasing during 10 min
of photobleaching experiment. The first 2 min are used to establish a baseline by imaging
YFP and Cer at 30 sec interval.
control sample transfected with only Cer-SERCA. These calibrations indicated a=0.074 and
d=0.70 in my experimental setup.
Each cell that expressed CFP and YFP above background threshold was plotted as
percent FRET over a range of expressed protein as determined by YFP intensity (in arbitrary units, A.U.). The plotted data were fit by equation: FRET=(FRETmax x IYFP)/(Kd+IYFP),
where IYFP is YFP intensity, FRETmax is maximum FRET, and Kd is the apparent dissociation
constant of the donor- and acceptor-labeled proteins for each other.
Another FRET technique used in investigation of protein-protein interactions is
progressive acceptor photobleaching. This method utilizes irreversible selective
destruction of the acceptor fluorophore through prolonged excitation. Once destroyed, the
acceptor fluorophore no longer can quench the donor emission (assuming FRET pair was in
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distance suitable for FRET), and donor fluorescence intensity increases (Patel et al., 2002).
Acceptor photobleaching experiments were performed on a similar set up as described for
acceptor-sensitized emission FRET, except that YFP was selectively photobleached by
exposure to YFP excitation (504/12nm bandpass filter) for 10 s, and then YFP and CFP
were imaged. The first 10 images were acquired in 10 s intervals without photobleaching
to obtain fluorescence intensities baseline values. Images were analyzed with ImageJ
software (Schindelin et al., 2012) by manually selecting cells. The fluorescence intensity
values were plotted over time either as arbitrary units (A.U.) or average intensity was
normalized to baseline intensity using the equation: F/F0=(F−Fbg)/(F0−F0bg), where F is the
fluorescence intensity after photobleaching, F0 is last baseline fluorescence intensity
recorded, and Fbg and F0bg are background fluorescence signals. Figure 5 shows a
representative field of cells expressing Cer-PLB and YFP-PLB and changes in their
corresponding fluorescence intensities before and after YFP photobleaching.
Live Cell Ca2+ Uptake Activity Assay
To evaluate Ca2+ transport activity of SERCA, I transfected AAV-293 cells with Cer-SERCA
and YFP-PLB DNA constructs and performed Ca2+ uptake activity assay as described
previously (Bidwell et al., 2011). 24 hrs post-transfection, cells were labeled with the cellpermeant Ca2+ indicator dye X-Rhod-1 (AM) (ThermoScientific, Waltham, MA). Transfected
and untransfected cells were distinguished based on the intensity of Cer and YFP
fluorescence emissions. Release of Ca2+ from ER stores was accomplished by stimulating
purinergic receptors with extracellular application of 200 μM ATP, which activated inositol
1,4,5-trisphosphate receptors on ER membrane (Dubyak and el-Moatassim, 1993).
Accumulation of Ca2+ in the cytosol was quantified as an increase in X-Rhod-1 fluorescence.
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SERCA Ca2+ transport activity was detected as decrease in ATP-stimulated cytosolic Ca2+
accumulation relative to untransfected cells. 4 min after application of extracellular ATP,
cells were treated with 50 μM TG to determine the size of the Ca2+ store remaining in the
ER.
Measuring Calcium Oscillations by Confocal Microscopy in Live Cells
AAV-293 cells were transiently co-transfected with three plasmids containing genes of
human GFP-Ryanodine receptor-2 (RyR), low affinity ER calcium sensor R-CEPIA1er, and
2-color canine SERCA2a wild type (WT) or triple loop mutant AAA (ratio of DNA constructs
was 3 unites of RyR to 1 unit of R-Cepia1er, and 10 unites of SERCA). Transfected cells were
cultured for 24 hrs and seeded into poly-D-lysine coated glass bottom chamber slides in
MDM. 24 hrs after seeding, media was changed with PBS with Ca2+/Mg2+ and experiments
were conducted with a Leica SP5 laser scanning confocal microscope equipped with a 63×
water objective. R-CEPIA1er was excited with the 543 nm line of a He-Ne laser, and emitted
fluorescence was measured at wavelength ≥580 nm. 2CS fluorophores Cer and YFP were
excited with the 430 and 514 nm lines of an Argon laser, respectively, and emitted
fluorescence was measured at wavelength ≥485±15 nm and ≥537±15 nm, respectively.
Images were acquired in line-scan mode for up to 8−12 min with addition of 10 mM
caffeine or 100 μM ionomycin (Iono) at 2 min. Fluorescence image analysis was performed
with Fiji (ImageJ) software (Schindelin et al., 2012).
To load cells with the low-affinity Ca indicator X-Rhod-1/AM (X-Rhod) (Lock et al.,
2015) cells were incubated with 10 μM X-Rhod (ThermoScientific, Waltham, MA) for 15
min in PBS with Ca2+/Mg2+. Before conducting experiments, cells were washed twice with
PBS with Ca2+/Mg2+.
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MRP-1 functional measurements were accomplished with Argon laser illumination
at 488 nm for GFP and DOX, and detection of emission bands of 496-522 and 565-650 nm
respectively.
All-atoms Molecular Dynamics Simulations
All-atoms MD simulations were performed with the GROMACS software package (Hess et
al., 2008; Pronk et al., 2013) with CHARMM 27 force field (MacKerell et al., 2000). TIP3P
water model (Jorgensen W. L. and L., 1983) was used to carry out MD simulations with an
integration time of 2 fs. The reference 1SU4 crystal structure of SERCA (Toyoshima et al.,
2000) was used to introduce Nβ5-β6 loop mutations and perform energy minimization
with the steepest descent method for 1000 steps. Then the structures were embedded into
a POPC lipid bilayer and solvated into triangular water box with dimension sizes 130 ´ 130
´ 160 Å. Na+ and Cl− ions were added to the solution to concentration of 150 mM. The
Berendesen method (Berendsen H. J. C., 1984) with relaxation time of 0.1 ps was used to
increase the temperature of the system to 300 K and to increase the pressure to 1 bar. After
1 ns equilibration, the production run was performed in the NPT assemble using the NoseHoover thermostat (Hoover, 1985; Nose, 1984) and the Parrinello-Rahman barostat
(Parrinello, 1981) with relaxation time of 1 ps. Six independent production runs for each
wild-type or mutant models were started with different sets of assigned velocities at 300 K.
The atoms coordinates were saved every 1 ps. The production runs were carried out for
100 ns.
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Structural Analysis and Visualization
The VMD program (Humphrey et al., 1996) was used for visualization and rendering
structures. The GROMACS (Hess et al., 2008; Pronk et al., 2013) program was used for the
computational analysis of secondary structures of AAMD run productions. The A-N
domains distance was computed as minimum distance between atoms of domain A(residues number 1−40 and 128−241) and atoms of N-domain (residues 360−603). The
number of contacts was calculated within 4 Å between atoms of A- and N-domains. A
contact of an N-domain atom with multiple atoms of A-domain was counted as one contact
(i.e., instead of multiple contacts). The first 10 ns of MD runs were considered as
equilibration time and not included into calculations (except for SERCA-PLB complex,
where whole trajectories were included into quantification).
Principal Component Analysis
To identify the major motions of the SERCA headpiece during MD trajectories, I aligned
SERCA structures using the 10-helix TM-domain as a reference and used principle
component analysis (PCA) (Amadei et al., 1993; Kitao et al., 1998; Tournier and Smith,
2003). In order to compare structural ensembles with respect to the same eigenvectors, I
combined three SERCA reference X-ray crystal structures (1SU4 (Toyoshima et al., 2000),
3W5B (Toyoshima et al., 2013) and 1VFP (Toyoshima and Mizutani, 2004)), six MD
trajectories of WT-SERCA, and six MD trajectories of AAA-SERCA into a single trajectory. To
obtain sets of eigenvectors and eigenvalues corresponding to principle components I built
covariance matrixes of the atomic fluctuations in GROMACS (Hess et al., 2008; Pronk et al.,
2013). The diagonalization of matrixes yielded the eigenvectors (which are principle
components) and their associated eigenvalues.
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Figure 6. The diagram of the SERCA domains angular autocorrelation vectors
sampling.
The domain hinge was used as a starting point of the vector, while the domain center of
mass- its end, and vector displacement was calculated over time. Hand-drawn cones
represent approximate sampling of vectors angular displacement.

Domain Orientation Calculation
The GROMACS program was used for the computational analysis of SERCA structures from
AAMD productions. To perform correlation analysis of domains orientation, I quantified the
orientation of the vector which connects the domain hinge and domain center of mass. I
computed the hinge disorder function defined as
𝜃6 (𝑡) = 8cos<= >
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where 𝑥 is N, A, or P domain. Thus, 𝜃6 (𝑡) defines the time-dependent orientation of each
domain relative to the starting orientation (Fig. 6).
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Root Mean Square Fluctuations Calculations (RMSF)
RMSF was calculated in GROMACS (Hess et al., 2008; Pronk et al., 2013) as the root mean
square fluctuations (i.e. standard deviation) of atomic positions in the trajectory after
fitting to TM-domain with a reference to structure at 10 ns.
Root Mean Square Deviation Calculations (RMSD)
RMSD was calculated in GROMACS (Hess et al., 2008; Pronk et al., 2013). SERCA structures
of production runs were aligned using 10-helix TM-domain as a reference. RMSD was
calculated for Cα positions with reference to starting structure at 10 ns.
AAV-293 Cell Microsomal Membranes Preparations
Microsomal membrane containing SERCA were isolated from AAV-293 cells infected (for
ATPase assay) or transfected (FRET measurement) with two-color SERCA constructs as
described (Clifford and Kaplan, 2009). Cells were grown to confluency on 7−10 x 150 mm2
dishes for 2 days, washed twice with PBS, harvested by scraping, and pelleted at 4°C for 10
min at 1000 × g. To prepare cell homogenate, the cell pellets were (1) resuspended in cold
homogenizing solution (0.5 mM MgCl2, 10 mM Tris-HCl pH 7.5, EDTA-free complete
protease inhibitor cocktail (Santa Cruz Biotechnology, Inc., Dallas, TX)), (2) disrupted in
Potter-Elvehjem homogenizer, (3) supplemented with equal volume of sucrose solution
(100 mM MOPS pH 7.0, 500 mM sucrose, EDTA-free complete protease inhibitor cocktail),
and (4) passed through a 27-gauge needle. To prepare microsomal membranes, (1) cell
homogenates were centrifuged for 10 min at 1000 × g at 4°C, (2) the low-speed
supernatants were centrifuged at 30 min at 55000 rpm (Beckman Coulter Optima
Ultracentrifuge, rotor TLA-110, ~ average 130000 × g), (3) the high-speed membrane
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Figure 7. Schematic representation of the enzyme-linked ATPase assay.
SERCA specific ATPase activity measured as a function of the rate at which NADH
absorbance at 340 nm is decreased. SERCA consumes ATP generated in pyruvate
production reaction by phosphoenolpyruvate and pyruvate kinase. Pyruvate is used in
lactic acid generation by lactate dehydrogenase, which oxidizes NADH in the process.
NADH depletion serves as an indirect measurement of SERCA ATPase activity.
pellets were resuspended in a 1:1 mix of homogenizing and sucrose solutions, and (4) the
membrane suspensions were passed through a 27-gauge needle. The protein concentration
of microsomal membranes was determined with Pierce BCA assay kit (ThermoScientific,
Waltham, MA). ATPase assay was performed the same day; otherwise, microsomal
membranes were aliquoted, snap-frozen in liquid nitrogen, and stored at −80°C. Light SR
(LSR) microsomal samples enriched in SERCA (approximately 90% of proteins in the LSR is
SERCA) were a gift from Dr. David D. Thomas at the University of Minnesota.
Ca2+-ATPase Functional Measurements
Two-color SERCA enzymatic activity was measured and quantified in microsomes by
spectrophotometric measurement of the rate of NADH consumption as a function of Ca
concentration in an enzyme-coupled activity assay in a 96-well plate (Lockamy et al., 2011;
Reddy et al., 2003). Figure 7 shows the schematic of the enzyme-linked ATPase assay. The
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time-dependent change of NADH absorbance was measured at 25°C in a PHERAstar FSX
microplate reader (BMG Labtech, Cary, NC) at 340 nm. Each well contained 3−4 μg of
microsomal membranes, 50 mM MOPS at pH 7.0, 0.1 M KCl, 5.0 mM MgCl2, 1.0 mM EGTA,
2.5 mM ATP, 0.2 mM NADH, 5 IU of pyruvate kinase, 5 IU of lactate dehydrogenase, and 0.7
μg of Ca2+ ionophore (A23187) (chemicals were obtained from SigmaAldrich, St. Louis,
MO). Free Ca2+ concentrations were calculated using Ca2+/Mg2+/ATP/EGTA Calculator from
Theo Schoenmakers’ Chelator (Schoenmakers et al., 1992). Data were fitted using a Hill
function: V=Vmax/[1+10−n(pKCa−pCa)], where V is the initial ATPase rate, n is the Hill
coefficient, and KCa is the apparent Ca2+ dissociation constant and Vmax was obtained from
the fit of the Hill equation at saturated Ca2+ concentrations.
Western Blotting
The protein concentrations were determined with a bicinchoninic acid protein assay (BCA)
(ThermoScientific, Waltham, MA) according to the manufacture’s instructions. Microsomal
membrane preparations were diluted in 2-fold SDS buffer (BioRad, Hercules, CA), heated at
55°C for 10 min and loaded on a 4−15% polyacrylamide precast gel (BioRad, Hercules, CA).
The proteins were separated at 110V for 1 hr and transferred to polyvinylidene difluoride
membrane at 4°C for one hr at 100 V. The membrane was blocked in Odyssey PBS blocking
buffer (LI-COR, Lincoln, NE) for one hr at room temperature followed by incubation with
primary antibody: mouse anti-SERCA2 (IID8, 1:1,000; Abcam, Cambridge, UK) or mouse
anti-PLB (2D12, 1:1,000; Abcam, Cambridge, UK) overnight at 4°C. Blots were incubated
with anti-mouse secondary antibodies IRDye680RD or IRDye800CW (1:10,000, LI-COR,
Lincoln, NE) for 1hr at room temperature. The blots were imaged using LI-COR Odyssey
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biomolecular imager and intensities were analyzed with Image Studio Lite Version 5.2
software (LI-COR, Lincoln, NE).
Ligand-induced Stabilization of SERCA Biochemical Intermediates
To fix SERCA in substrate-stabilized biochemical intermediates, various substrate solutions
were prepared by addition of corresponding substrates to the calcium-free base solution
which included KCl 100 mM, Imidazole 10 mM, MgCl2 5 mM, EGTA 2 mM, pH 7.0 (KOH).
The following ligands were used to prepare specific solutions corresponding to SERCA
biochemical state (in parenthesis): 100μM thapsigargin (E2-TG), 3mM ATP (E1-ATP), 2.1
mM CaCl2 (E1-2Ca) with free [Ca2+]i=100 μM); 2.1 mM CaCl2 and 3 mM ATP (E1-2Ca+ATP);
2.1 mM CaCl2 and 3 mM ATP non-hydrolysable analog AMP-PCP (E1-2Ca+AMMPPCP); 2.1
mM CaCl2, 3 mM ADP, 3mM KF and 50 μM AlCl3 (E1P-2Ca+AlF−+ADP); 0.1 mM
orthovanadate (E2-Vi); 50 μM AlCl3 and 3 mM KF (E2-AlF4−). Chemicals were obtained
from SigmaAldrich, St. Louis, MO.
To measure SERCA intramolecular FRET in ligand-stabilized biochemical
intermediates, 1μl of membrane preparations (7−10 μg total protein concentration) was
thawed on ice and mixed with 9 μl of substrate solutions and immediately imaged using
fluorescent microscopy, as described above.
MRP-1 Functional Measurements
I measured doxorubicin (DOX) extrusion from GFP-MRP-1 expressing cells to determine
function of MRP-1 in the presence of candidate modulators. Transiently transfected cells
plated on glass-bottom coverslip were pre-incubated with 10 μM each candidate
compound for 15 min, and then 2 μM DOX was added for 1 hour. Cells were imaged by
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confocal microscopy, and the intensity of the red fluorescence was used as an index of DOX
accumulated in the cell nucleus. Cells expressing MRP-1 were identified by the presence of
GFP fluorescence and compared to cells in the same field.
Statistical Analysis
Data are presented as the mean ± S.E.M. of ≥ 3 experiments unless specified in figure
legend. All statistical tests were done using OriginPro 9.1 (OriginLab Corporation,
Northampton, MA). Student's t test (unpaired two-tailed) was used to compare the
difference between two groups, one-way analysis of variance (ANOVA) was used to
compare the difference between three or more groups, and two-way ANOVA was used to
compare the difference between different groups under different treatment conditions.
ANOVA was followed by Tukey's post hoc test. A probability (p) value of <0.05 was
considered significant.

CHAPTER THREE
SERCA STRUCTURAL DYNAMICS DURING CALCIUM TRANSPORT
All-atom Molecular Dynamics Simulations of SERCA Point Mutants
Previous MD simulations of SERCA spontaneous movements indicated that a SERCA
headpiece open-to-closed transition was initiated by an interaction between the A-domain
and the Nβ5-β6 loop of the N-domain via electrostatic/H-bond interactions (Smolin and
Robia, 2015a). The Nβ5-β6 loop (426-DYNEAKGVYEK-436) was predicted to help in
piercing the poorly-diffusible water layer and to support a stable, ordered arrangement of
the N- and A-domains during Ca2+ cycling. When this loop was mutated in silico to remove
the three negative charges (D426A/E429A/E435A, or AAA), SERCA was not able to obtain
closed conformations.
To further investigate the role of Nβ5-β6 loop in SERCA headpiece dynamics, I
extended these simulations for WT- and AAA-SERCA from 40 ns up to 100 ns as a more
physiologically relevant time point, and performed additional simulations of SERCA Nβ5-β6
loop single-point mutants. Fig. 2 shows the starting structure of SERCA used for MD
simulations (PDB accession code 1SU4 (Toyoshima et al., 2000)), highlighting the A-, N-, P-,
and TM-domains, plus the Nβ5-β6 loop.
First, I examined SERCA global structural dynamics to confirm that the gross
structure and motions of SERCA were not disrupted by the introduction of loop mutations.
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Figure 8. RMSD and RMSF of SERCA structural dynamics calculated from MD
simulations.
(A) SERCA N- (orange), A- (blue), P- (grey) and TM- (black) domains showed similar Cα
RMSD fluctuations for SERCA WT and all mutants. (B) Global Cα RMSD fluctuations of the
most dynamic SERCA N-domain revealed similar motions. (C) Quantification of B. (D)
Quantification of RMSF of Cα atoms revealed that nucleotide-binding domain was the most
mobile domain with similar relative structural dynamics for all SERCA structures. Highlymobile cytosolic regions and stable TM regions are labeled by letters and arrows (bottom):
WT-SERCA (black), AAA (red), D426A (blue), E429A (green), and E435A (magenta). Data
represent the average of 6 MD run productions for each SERCA construct.

I observed comparable domain RMSD for WT-, AAA- and SERCA point mutants,
indicative of similar domain dynamics (Fig. 8A). Although the N-domain was the most
dynamic, no substantial differences in its motions were observed between SERCA starting
structures (Fig. 8B-C). SERCA Cα atoms RMSF, that present residue-by-residue motions,
showed higher RMSF values for N-domain (Fig 8D). This observation also confirms that Ndomain is the most dynamic for all SERCA structures. Nevertheless, all of the SERCA
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structures had dynamics comparable to WT as shown in Fig. 8D by overlapping plots. Small
RMSF increases (like for the A-domain’s and TM-helix’s residues for point mutants in Fig.
8D) was regarded as non-significant changes compared to RMSF changes reported for
SERCA different structures 1SU4, 1WPG, and 2ZBD (Smolin and Robia, 2015a).
To inspect SERCA dynamics in more detail, I calculated angular autocorrelation of
cytoplasmic domains for all SERCA structures, and compared the relative motions of the
cytoplasmic domains to the starting orientation. This analysis allowed sampling of
domains’ redistribution in the space and detected larger dynamics for N-domain as
represented by larger angle values (Fig. 9A top panel). A-domain had the intermediate
rotational dynamics (Fig. 9A center panel), while P-domain presented with smallest
angular correlation values (Fig. 9A bottom panel). Similar angular autocorrelation values
were observed for the WT and mutant SERCA structures for all of the domains (Fig. 9A),
indicating the preservation of the cytosolic domains’ dynamics upon mutations.
Fig. 9B shows representative covariance matrices for WT-SERCA (upper left) and
AAA-SERCA (lower right) as a residue-by-residue correlation of transporter motions. If
residues move in the same direction (follow each other), they are considered to be
positively correlated and presented in red color, while negative correlations represent
motions in the opposing directions (toward or away from each other) and colored in blue. I
observed a positive self-correlation within N-domain (residues 369-603) for all structures
(Fig. 9B, red). This observation was expected, as generally the domain residues move in the
same direction as a part of the whole domain. On the contrary, the correlation between the
N- and A-domains was negative for WT-SERCA due to independent motions of these
domains in opposing directions. Interestingly, motions of AAA-SERCA A- and N-domains
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Figure 9. The relative motions of SERCA domains are preserved upon Nβ5-β6 loop
mutations.
(A) Angular autocorrelation of the cytoplasmic domains during 100 ns production runs.
Data represent the average of 6 MD runs. (B) Representative covariance matrices Cα
atoms for WT-SERCA (upper left) and AAA-SERCA (lower right). Covariance analysis of
WT-SERCA residue dynamics as measured from Cα revealed positively (red) and negatively
(blue) correlated motions. For AAA-SERCA, covariance analysis indicated similar global
dynamics yet reduced anti-correlated A-domain motions compared to WT-SERCA.

had null correlation (Fig. 9B, white), indicative of reduction of dependent motions of these
domains. This observation that AAA-SERCA has reduced correlation between A- and Ndomains motions signify that Nβ5-β6 loop mutations decrease domain-to-domain
dependent dynamics. Besides that element, the rest of the WT-and AAA-SERCA structural
motions were similar.
Even though the primary SERCA structural dynamics were conserved, the
quantitative analysis of MD trajectories proved a very specific structural effect of Nβ5-β6
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Figure 10. SERCA loop mutations increase A- and N-domains separation in silico.
WT-SERCA (black), AAA (red), D426A (blue), E429A (green), E435A (pink). Data represent
average of 6 MD run productions. (A) Number of contacts between the N- and A-domains
during MD trajectories. (B) Distribution of data in (A). (C) AAA-SERCA shows an increase in
N–A-domains separation distance compared to WT-SERCA. (D) Distribution of data in (C).
(E) Negative correlation of separation distance on domain–domain contacts, from results in
(A) and (C). Pearson correlation r = −0.99, p=0.002, * p=0.037 for number of contacts.

loop mutations on the separation of the SERCA headpiece domains. In particular,
substitution of three negative Nβ5-β6 loop residues to alanine decreased the N- and Adomains contacts (Fig. 10A) and increased minimal distance (Fig 10C). Figures 10B and
10D show distribution of sampled trajectories. When means of six trajectories for each of
the number of contacts and distance between A- and N-domains were plotted against each
other, the domains minimal distance and the number of contacts showed a negative
correlation (r = −1) for WT-SERCA structure (Fig. 10E, black). This observation means that
a short distance between domains was maintained by a large number of contacts. On the
contrary, AAA-SERCA structure showed an opposing negative correlation presented by a
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large domain separation and significantly fewer contacts (Fig. 10E, red). The single-point
mutants were well-tolerated and resulted in intermediate phenotypes between AAA and
WT values for domain-domain separations (Fig. 10E. blue, green, and magenta). This result
supports the importance of Asp426, Glu429 and Glu435 residues in SERCA structural
assembly.
Interestingly, single point mutant Glu429A had shown number of contacts between
A- and N-domains comparable to WT, but increased domains separation (Fig. 10E, green).
This observation suggests that one or both of the remaining residues, Asp426 and/or
Glu435, are redistributed in space to form a large number of contacts, while keeping
domains apart. Considering the fact that Glu429 is at the very tip of the SERCA Nβ5-β6 loop
(Fig. 1), it is likely that residue Glu429 is the first residue of the N-domain to interact with
the A-domain, and this residue may be defining for the decrease in the distance between
cytosolic domains.
In conclusion, my in silico analysis of SERCA spontaneous motions detected
preserved gross dynamics of SERCA mutants compared to WT (Fig. 8-9), suggesting
maintenance of structural assembly upon introduction of mutations. On the other hand,
SERCA A- and N-domains separation was significantly increased by removal of the Nβ5-β6
loop negative charges (mutation of Asp426, Glu429 and Glu435 to Alanine), which was
aimed to prevention of the salt bridges/H-bonds between the Nβ5-β6 loop and the Adomain basic/positive residues. Thus, my all-atoms MD simulations implicated the Nβ5-β6
loop as a discrete structure that regulates SERCA headpiece closure (Fig. 10). Next, I set up
to determine what effect this structural deficit in the cytosolic headpiece closure has on the
transporter structural dynamics.
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Figure 11. First and second principal components of SERCA structural dynamics.
(A) Black arrows represent first and second principal components of SERCA domain
motions. Plus and minus signs correspond to coordinates labels in (B). (B) Relative
sampling of the top two principal components by WT-SERCA (black) and AAA-SERCA (red)
trajectories. Each point represents a conformation extracted from the MD trajectories at an
interval of 0.1 ns. For comparison, grey dots represent X-ray structures with open (1SU4),
closed (1VFP), and intermediate (3W5B) headpiece conformations.

Comparison between Structural Dynamics of WT- and AAA-SERCA
To examine in detail SERCA motions and the effect of Nβ5-β6 loop mutations on SERCA
structural dynamics, I performed a principal component analysis (PCA) of the ensembles of
WT-and AAA-SERCA trajectories. PCA analysis determines how each trajectory sampled the
major motions compared to the starting structure. Here I present two most dominant
motions, PC1 (48% of all motions) and PC2 (15% of all motions). The principal motion PC1
was SERCA headpiece opening/closing, while the second major motion PC2 was twisting of
the cytoplasmic domains. Fig. 11A summarizes positive and negative motions of the A- and
N-domains along each component. To visualize the distribution of PC1 and 2, I plotted them
against each other for each structure sampled every 10 ns in all of the trajectories (Fig.
11B). As a result, 6 different WT-SERCA trajectories sampled values ranging from -36 Å
(closed) to +25 Å (open) (Fig. 11B9G, black), while 6 different AAA-SERCA trajectories (Fig.
11B, red) showed more population of open structures at the expense of closed
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Figure 12. Principal component analysis for WT- and AAA-SERCA.
(A) Sampling of the first and second principal components for six WT-SERCA (black)
trajectories and six AAA-SERCA (red) trajectories. Each graphical point (black and red)
represents a structure extracted from trajectories at a time interval of 0.1 ns over the time
course of 100 ns simulations. Turquoise dots indicate selected structures (shown in inset)
from each structural quadrant. The arrows represent specific motions of the N-domain
(yellow) and A-domain (blue). (B, C) Individual PC analysis for WT-SERCA (B) and AAASERCA (C), where the six different colors represent each of six individual MD simulations.
conformations (minimum of -30 Å, maximum of +31 Å). This result is consistent with the
observed increased separation between N- and A-domains upon Nβ5-β6 loop mutations
(Fig. 10). Along the second dominant motion PC2 axis (twisting of the cytoplasmic
domains), WT showed several trajectories ranging from -27 to +23 Å, which was 56%
greater than the range of AAA-SERCA along PC2 (from -14 to +18 Å) (Fig. 11B). Individual
trajectories for WT- and AAA-SERCA are highlighted in different colors in Fig. 12B and C
respectively and show a wider distribution of individual WT trajectories. The
representative structures were extracted at the representative point of trajectory in each of
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the quadrants as in figure 12A (green dots) and represent the conformational extremes.
Overall, PCA indicates that the AAA-loop mutations decrease the range of motions of SERCA
cytosolic domains along the first two principal components and shifts the population of
structures toward a more open ensemble.
Additionally, I looked into SERCA headpiece ensemble in more detail by examining
separation of cytosolic domains (Fig. 13). Minimal distance between A−N-domains was
increasing over time, while distances between P- and A-domains or P-and N-domains were
not changed (Fig. 13A). This result suggests that while A- and N-domains are separate from
each other, it is the P-domain that retains contacts with both A- and N-domains constantly.
Separation of A−N domains was expected due to high RMSD of these domains, especially Ndomain (Fig. 8A). Consistent with the preceding observation (Fig 13A), numbers of contacts
between P−N or P−A-domains were the highest, and I observed their matching changes
along the trajectories (Fig. 13B). This result indicates that the P-domain may serve as an
anchoring structure for cytosolic domains, while A- and N-domains separate from each
other in distance (Fig. 13A) but still retain a minimal number of contacts (Fig. 13B). This
deduction may be an alternative hypothesis to my earlier observation that residue Glu429
is critical for A- and N-domains minimal distance decrease (Fig. 10E).
Analysis of distance between each domain’s center of mass shows redistribution of
domains in space. Specifically, I observed the same pattern for A−N and P−N-domains
separation, while the P−A-domains position remained unchanged, which suggests that the
P-domain is moving together with the A-domain, and they both follow more dynamic N-
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Figure 13. SERCA headpiece domains structural dynamics.
Separation between domains: black traces for A−N and P−N domains, while P−A is in grey.
(A) Minimal distance between A−N-domains is increased compared to P−A and P−Ndomains. (B) Number of contacts between the domains during MD trajectories are very
stable. (C) Distance between A−N and P−N-domains change simultaneously, while distance
between P−A-domains does not change. Data present average of 6 MD run productions.
domain motions. Overall, this analysis gives more insight on SERCA cytoplasmic dynamics:
the P-domain serves as an anchoring structure for A- and N-domains, and dynamic motions
of N-domain are principal for structural changes in remaining cytosolic domains.
Overall, my MD simulations detected a decrease in SERCA structural dynamics for
the Nβ5-β6 loop triple mutation. Specifically, PC1 analysis sampled more open
conformations in the expense of the closed ensembles, while PC2 had overall decreased
distribution (Fig. 11-12). I believe that the direct consequence of the AAA-SERCA reduced
dynamics is the observed deficit in AAA-SERCA headpiece closure (Fig. 10) and the Nβ5-β6
loop serves as SERCA structural determinant. Additionally, analysis of SERCA cytosolic
domains’ spatial distribution suggested that P-domain serves as a coordinating domain
between highly dynamic A−N-domains (Fig. 13). These insights into SERCA structural
dynamics and identification of the Nβ5-β6 loop as SERCA structural determinant are
important for understanding transporter function, which will be examined next.
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Figure 14. N-domain β5-β6 loop triple mutation decreases SERCA function.
(A) Ca2+-ATPase assay of microsomes from cells expressing WT- or AAA-SERCA. (B) Ca2+
sensitivity of ATPase activity (KCa), as in (A). (C) Maximal Ca2+-dependent ATPase rate
(Vmax), as in (A). * p<0.015. (D) Western blotting confirms SERCA viral expression in
microsomes used for ATPase assay. (E) Ca2+-ATPase assay of preparations of control light
sarcoplasmic reticulum (LSR, blue) or microsomes from cells expressing GFP (pink).
The Role of the Nβ5-β6 Loop in SERCA ATPase Activity
To determine the possible functional significance of the Nβ5-β6 loop, I prepared
microsomal vesicles from AAV-293 cells expressing 2-color WT-SERCA or AAA-SERCA and
measured Ca2+-dependent ATPase activity. Fig. 14A shows a representative example of n =
4 independent experiments and demonstrates that the maximal activity of AAA-SERCA was
decreased. Quantification of all 4 experiments yielded a 63±5% difference in ATPase
maximal rate between WT and AAA transporter (p = 0.015) (Fig. 14C). This result is
consistent with the previous finding by Inesi lab that mutation of Asp426 to Ala decreased
SERCA ATPase activity by 61% (Inesi et al., 1988). Based on KCa values of 7.2±0.2 (WT) and
7.1±0.3 (AAA), the apparent Ca2+ affinity of AAA-SERCA was not significantly different from
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that of WT-SERCA (p = 0.61) (Fig. 14B). I detected 2-color SERCA viral expression in
microsomal preparations by the Western blotting analysis (Fig 14D). Since I observed a
band for endogenous SERCA, I confirmed that endogenous SERCA activity was not
significant and thus negligible by measuring Ca2+-dependent ATPase activity in microsomes
from AAV-293 cells transduced with control GFP vector (Fig. 14E, pink).
Overall, the data indicate that SERCA ATPase activity is decreased by mutations of
negatively charged loop residues; nevertheless, the mutated transporter is still able to
perform a complete enzymatic cycle. This functional ATPase assay confirmed the
significance of the Nβ5-β6 loop in SERCA ATPase activity in vitro. To further investigate
SERCA structural intermediates during the ATPase enzymatic cycle, I performed in vitro
structural measurements of SERCA transitional states in the substrate-stabilized
environment.
Quantification of FRET of 2-color SERCA Expressed in Microsomal Membranes
It has been previously demonstrated that 2-color SERCA FRET is increased with
increasing Ca2+ (Hou et al., 2012). I performed 2-color FRET measurements in microsomal
membranes prepared from AAV-293 cells expressing WT-SERCA with controlled Ca2+
concentrations. Fig. 15A shows that increasing Ca2+ resulted in a progressive shift toward a
higher FRET values. The WT 2-color SERCA FRET response to Ca2+ had a KCa of 1.25±0.22
μM, which was different from 0.1 μM value obtained for the ATPase assay. I attribute this
nearly 12-fold difference in KCa to the different composition of buffers for different assays.
Even though I calculated free Ca2+ concentration using the Ca2+/Mg2+/ATP/EGTA Calculator
from Theo Schoenmakers’ Chelator (Schoenmakers et al., 1992), it is not uncommon to
observe a 10-fold discrepancy in KCa between published reports (Hou et al., 2012; Hughes
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Figure 15. SERCA structural dynamics measured by FRET in microsomes.
(A) WT 2-color SERCA showed an increase in FRET with Ca2+ increase. (B) FRET of 2-color
SERCA stabilized in key enzymatic states. (C) FRET values for SERCA E1 and E2
conformers. Yellow highlights E1 states, while green highlights E2 states. Data represent at
least 5 independent experiments. (D) Real-time measurements of SERCA FRET upon
addition of Ca2+ with ATP solution shows SERCA FRET decrease and eventually gradual
recovery. Red line represents exponential FRET recovery by Hill1 fit. Data represent 12
cells from 2 independent experiments.

and Middleton, 2014; Sahoo et al., 2015; Sahoo et al., 2013; Shaikh et al., 2016). The
observed Hill coefficient of 0.76 suggests the apparent lack of cooperativity, which is
consistent with the proposition that the structural transition from low- to high-affinity
states is complete after binding of the first Ca2+ to the transport site I (Cantilina et al., 1993;
Chen et al., 2006; Henderson et al., 1994a; Henderson et al., 1994b; Inesi et al., 1988;
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Figure 16. Modified Post-Albers reaction cycle.
Blue boxes enclose states with similar intramolecular FRET efficiencies. E1 state are yellow
and E2 states are green. Major transitional states are shown in black, while grey represent
non-physiological state (TG-bound. E2-TG) and alternative pathway (Ca2+ binding prior to
ATP binding, E1-2Ca). (a) ATP binding induces conformational changes that facilitate Ca2+
binding at the cytosolic membrane side. (b) P-domain phosphorylation and ATP
hydrolysis. (c) Ca2+ release at the other side of membrane. (d) Dephosphorylation. (e) ATP
binding. Steps (c-d) are predicted to be the slowest steps.
Trieber et al., 2009). Overall, the data are compatible with my previous observation that
upon increase in Ca2+ concentration with ionophore treatment, 2-color SERCA exhibit a
high FRET compact state (Hou et al., 2012).
To investigate SERCA intermediates in the ATPase enzymatic cycle, I stabilized Ca2+
transporter conformers with biochemical substrates (MacLennan et al., 1997). I observed
low FRET in the presence of ligands for the E2 (low Ca2+ affinity) intermediates and high
FRET in the presence of ligands for E1 (high Ca2+ affinity) states. Specifically, E2-H+
(protonated SERCA) showed 9.9±0.6% FRET, and E2-TG, which locks SERCA in the Ca2+free E2 state (Sagara et al., 1992a; Sagara et al., 1992b) resulted in 10.3±0.5% FRET. E2P,
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phosphoenzyme intermediates, (E2-AlF4– and E2-Vi) showed even lower ~8% FRET. In
contrast, I observed higher FRET (above 15%) for microsomes in E1 states: E1-ATP, E12Ca, E1-2Ca+ATP, 2Ca+AMP-PCP, and E1-2Ca+ADP+AlF4–. The FRET values for each state
are summarized in Table 1 (Fig. 15C). Overall, these data indicate that SERCA E1
conformers are more compact, while E2 conformers are more open headpiece
conformations.
SERCA progression through the Ca2+ transport cycle is powered by ATP hydrolysis.
In my FRET detection of biochemically-stabilized conformers in SERCA-rich microsomal
membranes I used 3 mM ATP, which is on the higher side of the physiological ATP
concentration. Nevertheless, I wanted to confirm that ATP remains non-depleted and I
detect true FRET values for the E1-ATP and E1-2Ca+ATP states. As an alternative to ATP, I
used non-hydrolysable ATP analog- AMP-PCP, which showed FRET similar to E1-ATP state
(~15%) (Fig. 15B). Additionally, I monitored FRET changes after ATP addition in real-time
and observed an initial decrease with following recovery in 2-color SERCA FRET (Fig. 15D).
I interpreted this result as a demonstration of several cycling SERCA phases: entering in
active cycling (decrease), build-up of luminal Ca2+ (increase), and steady-state cycling with
inhibition by high luminal Ca2+ or build-up of ADP (plateau) (Inesi and de Meis, 1989).
Based on these findings, it is most likely that in Fig. 15B for E1-2Ca+ATP state I was
measuring a plateau steady-state cycling phase when SERCA is continuously cycling
following addition of activated solution (2Ca+ATP) as in Fig. 15, and while ATP is not
depleted, but rather significant ADP build-up results in SERCA accumulation in this
compact conformation.

46
SERCA FRET measurements in a substrates-stabilized environment allowed
identification of SERCA headpiece structural conformers for several intermediate states
during Ca2+ transport (Fig. 15). As a result, in Fig. 16 I present a Post-Alberts reaction cycle
supplemented with my data. I highlighted states with similar intramolecular FRET
efficiencies in blue boxes: E1 states (yellow) have high FRET (~15%), while E2 states
(green) have predominantly low FRET (~8-10%). My data demonstrates compact SERCA
E1 conformers, while E2 conformers have more open headpiece conformation and indicate
a shift in SERCA conformers depending on ligand presence during specific cycle steps. To
provide complementary details for SERCA structural dynamics in physiological conditions,
I next detected FRET responses to regulated Ca2+ levels in live cells.
SERCA Structural Dynamics in AAV-293 Cells
To determine if SERCA headpiece structural differences observed in MD simulations and in
vitro were present in the cells, I used widefield microscopy and acceptor-sensitized FRET
to measure SERCA headpiece dynamics in AAV-293 cells in response to Ca2+ elevations. The
average basal FRET for 2-color SERCA was significantly lower for AAA- and all point
mutant SERCA structures compared to WT-SERCA (Fig. 17A), which is indicative of a more
open headpiece conformation upon N5β-6β loop mutations and supports my MD
calculations (Fig. 10). It is remarkable that single point mutants D426A, E429A, and E435A
showed decreased basal FRET intermediate between WT- and AAA-SERCA, which is
consistent with intermediary opened headpiece phenotype I observed for these mutants in
MD simulations (Fig10E). Thus, 2-color SERCA intramolecular FRET measurements in cells
show the same specific structural effect of Nβ5-β6 loop mutations on separation of the
SERCA headpiece domains as in my MD data.
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Figure 17. SERCA headpiece structural dynamics measured by FRET in AAV-293 cells.
(A)Basal FRET of live cells expressing 2-color SERCA, * p≤0.005. (B) TG addition reduced
FRET for WT and all mutants, but vehicle control (Ctrl, dark blue) had a minimal effect. (C)
Addition of the Ca ionophore ionomycin (Iono) resulted in a biphasic FRET response for
WT and single-point mutants, as detected using epifluorescence microscopy. AAA-SERCA
(red) showed only the first phase: a decrease in FRET. Data represent 6-25 cells for each
condition. (D) Tau determined for phase 2 FRET recovery for data presented in (C), while
for AAA-SERCA lacking phase 2, tau was not determined (n/d).
Our lab had previously shown that 2-color SERCA FRET is markedly decreased with
binding to TG (Hou et al., 2012). In accordance with this result, the average FRET observed
for WT-, AAA-SERCA and all point mutants decreased momentarily with addition of 50 μM
of TG (Fig. 17B). This decrease in average FRET indicates that TG binding at TM-domain
induced structural changes in SERCA cytosolic headpiece. Thus, I believe the protein
structure is intact and preserved after loop mutation. Notably, addition of DMSO vehicle did
not result in FRET change (Fig 17B, navy).
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Application of the Ca2+ ionophore ionomycin (Iono) allowed influx of Ca2+ into the
cells expressing 2-color WT-SERCA and resulted at first in the immediate FRET decrease
(phase 1 in Fig. 17C, black) and secondly, in the slow FRET recovery to around the starting
FRET value (phase 2 in Fig. 17C, black). This observation indicates that rapid Ca2+ increase
allows reorganization of SERCA population into a very open conformation, followed by
emerging of closed SERCA conformers until reaching an equilibrium of mixed SERCA
ensembles within a few minutes. All point mutants behaved similar to the WT-SERCA
population in response to Iono (Fig17C, blue, green and pink) with similar kinetics of phase
2 FRET recovery (Fig.17D). In contrast, AAA-SERCA only exhibited phase 1 FRET change
and was lacking recovery phase 2 (Fig17C, red). This result indicates that the mutation of
just one of the negative residues of N5β-6β loop is not enough to abolish SERCA headpiece
closure, while removal of all three negative H-bonding residues from the N5β-6β loop has a
detrimental effect on SERCA obtaining compact state. Since AAA-SERCA responded
normally to TG, I believe that the deficit in phase 2 of FRET change in response to Ca2+
influx was not due to a global structural defect, but instead due to lack of H-bonding N5β6β loop residues that are regulate SERCA headpiece closure.
One of the future directions for this study is the detection of FRET during real-time
structural changes that SERCA undergoes with addition of Ca2+ (or other substrates) in a
fast-flow set up (Schaaf et al., 2017). These measurements will allow the detection of
SERCA intermediate states in real-time with the variety of substrates and will significantly
enhance the scientific understanding of SERCA structural dynamics during Ca2+ transport.
Overall, the in-cells FRET data (Fig. 17) are compatible with the MD simulation
analysis that detected a significant defect in SERCA headpiece closure for AAA-SERCA,
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while the point mutants exhibited intermediate between WT and AAA, or similar to WTSERCA phenotype (Fig. 10). In discussion chapter I will further elaborate on the observed
SERCA phase 1 and 2 FRET changes in response to sustained Ca2+ influx. To advance
scientific understanding of structural rearrangement that SERCA has to undergo during
Ca2+ cycling, I simultaneously monitored real-time changes in SERCA intramolecular FRET
and spontaneous Ca2+ oscillations in the cytosol or ER in live cells.
SERCA Conformational Changes in Response to Intracellular Ca2+ Dynamics
To monitor simultaneous real-time changes in SERCA intramolecular FRET and
spontaneous Ca2+ fluctuations, I utilized the muscle-like system as described previously
(Bovo et al., 2016). Briefly, I reconstituted elements of muscle cell Ca2+ handling in AAV293 cells by co-expression of GFP-RyR and 2CS. Ca2+ was monitored in the cytosol with Xrhod-1 Ca2+ indicator or in the ER with low-affinity Ca2+ sensor R-CEPIA1er by confocal
microscopy. SERCA conformational changes were detected as anti-correlated changes in
Cer and YFP fluorescence (Fig. 18A) and intramolecular FRET was quantified as the
YFP/Cer fluorescence ratio (Fig. 18B). In preceding experiments I observed high
intramolecular FRET measured in microsomal membranes in the presence of high Ca2+ and
for all E2-2Ca states (Fig. 15A-B), as well as accumulation of SERCA in high FRET state after
Iono treatment (Fig. 17C). Thus, I expected to detect high intramolecular FRET correlated
to elevation of cytosolic Ca2+ during spontaneous Ca2+ release events. Surprisingly, Ca2+
elevations in the cytosol corresponded to decreases in FRET (Fig. 18B), suggesting that
SERCA population shifted to an open conformation. Similarly, SERCA intramolecular FRET
dropped at the same time when ER Ca2+ store was at the lowest (release event) (Fig. 18C),
indicating that SERCA cytosolic headpiece shifted towards open conformation during Ca2+
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Figure 18. SERCA structural dynamics in response to spontaneous Ca2+ events
measured by FRET in AAV-293 cells.
(A) Anti-correlated changes in Cer and YFP fluorescence intensity indicate rhythmic FRET
fluctuations in intact cells. (B) The ratio of YFP/Cer, as in (A) was used as an index of FRET
(top panel, grey). FRET was inversely correlated to cytosolic Ca2+, as measured by X-Rhod-1
fluorescence (black, bottom panel). (C) A decrease in 2-color SERCA intramolecular FRET
(top trace) occurs simultaneously with depletion of ER Ca2+ stores (bottom trace). (D) AAASERCA FRET decreased during spontaneous cytosolic Ca2+ elevations.
elevation in the cytosol. I noticed that while SERCA intramolecular FRET decrease was
instantaneous at the moment of spontaneous Ca2+ release events (Fig. 18B-C), FRET
increase happened in the middle of the gradual increase in ER Ca2+ before the full
restoration of ER Ca2+ stores (Fig. 18C). This observation indicates that the ER continues to
fill even after SERCA FRET is reverted to baseline and cytosolic Ca2+ is returned to its
lowest (Fig. 18B). I believe that this phenomenon is due to the activity of store-operated
Ca2+ entry mechanisms that function irrespective of cytosolic Ca2+ levels to fill ER Ca2+ store
(Hogan and Rao, 2015). Nevertheless, the biggest paradox was the observation of SERCA
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Figure 19. SERCA structural dynamics in response to transient and sustained Ca2+
elevation measured by FRET in AAV-293 cells.
(A) After addition of Iono, both cytosolic Ca2+ and WT-SERCA FRET increased. (B) Addition
of caffeine (Caf) transiently increased cytosolic Ca2+ and decreased WT-SERCA FRET. (C) In
contrast to WT-SERCA FRET, AAA-SERCA FRET decreased with addition of Iono. (D) AAASERCA FRET increased in response to caffeine, similar to WT-SERCA FRET (F).
intramolecular FRET decrease upon cytosolic Ca2+ increase, as I expected the complete
opposite.
In addition to observed anti-correlated FRET/Ca2+ oscillations paradox during
transient Ca2+ elevations, AAA-SERCA showed similar to WT anti-correlated intramolecular
FRET/ intracellular Ca2+ oscillations (Fig. 18D). This observation was the opposite from
what I expected based on my previous results when I observed that AAA-SERCA has a
deficit in obtaining high FRET compact conformation in response to persistent Ca2+ influx
upon Iono treatment (Fig. 17C, red).
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I detected the same unexpected anti-correlated FRET and Ca2+ fluctuations during a
different experimental set which was aimed to induce a transient cytosolic Ca2+ increase.
The transient cytosolic Ca2+ elevation was triggered by treating cells expressing GFP-RyR
and 2-color SERCA with caffeine (Caf), a RyR activator, which resulted in an immediate
increase in cytosolic Ca2+ and its rapid decrease to a low level of cytosolic Ca2+ (Fig. 19B)
due to activation of plasma membrane Ca2+ extruders. As expected for transient Ca2+
elevation, this event was mirrored by anti-correlated FRET changes (rapid decrease, then
sustained increase). Again, opposing my previous observations that Nβ5-β6 loop triple
mutant was not able to obtain high FRET compact conformation (Fig. 17C), AAA-SERCA
reacted similarly to WT-SERCA to Caf-induced transient increase in cytosolic Ca2+,
presenting an initial FRET decrease which was followed for FRET increase (Fig. 19D).
To further investigate these unexpected observations, I measured SERCA response
to Iono immediately after detecting unexpected anti-correlated FRET and cytosolic Ca2+
fluctuations. First, I monitored the puzzling negative correlation in SERCA intramolecular
FRET and cytosolic Ca2+ levels for both WT- and AAA-SERCA before the addition of Iono
(Fig. 19A, C). Then, immediately after Iono addition, WT-SERCA intramolecular FRET
exhibited a biphasic response (rapid decrease and slow increase) (Fig. 19A), and AAASERCA intramolecular FRET only presented phase 1 (rapid decrease) and was lacking
phase 2 of FRET recovery (Fig. 19C), as observed earlier (Fig. 17C). Combining FRET
measurements during transient and then sustained Ca2+ elevations in one experiment
showed that both of the opposing FRET changes indeed take place. Since the major
difference that was determining the FRET change directions in response to Ca2+ elevations
was the level of Ca2+ influx, I concluded that the anti-correlated FRET and cytosolic Ca2+
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Figure 20. SERCA FRET changes in response to intracellular Ca2+ dynamics is not due
to intermolecular FRET
(A) Quantification of intermolecular FRET between Cer-SERCA and YFP-SERCA molecules
using progressive photobleaching (started at black arrow). Data presented are the mean of
F/F0 of Cer and YFP fluorescence in 6 cells. (B-C) SERCA intermolecular FRET did not
change with spontaneous Ca2+ release events (bottom trace) (J) or in response to Iono
addition (K).
oscillations are characteristic for transient Ca2+ elevations, while correlation between FRET
and cytosolic Ca2+ levels is a distinctive response to sustained cytosolic Ca2+ increase. Thus,
the anti-correlated simultaneous FRET and cytosolic Ca2+ fluctuations are observed during
transient intramolecular Ca2+ dynamics.
It is noteworthy, that intracellular spontaneous Ca2+ oscillations were hard to detect
in cells expressing AAA-SERCA compared to cells transfected with WT-SERCA. Additionally,
in those AAA-SERCA cells that displayed intracellular spontaneous Ca2+ fluctuations, the
frequency of Ca2+ release events was lower compared to cells transfected with WT-SERCA
(compare Fig. 18B vs. 18D). These observations demonstrate that in AAA-SERCA cells, ER
Ca2+ stores are not sufficient to activate RyR for spontaneous Ca2+ release, and/or AAASERCA has slower Ca2+ transport kinetics and requires longer time to fill in the ER lumen
than WT-SERCA. I propose that these functional deficiencies arise from the AAA-SERCA
defective headpiece closure mechanism.
It has been reported that SERCA forms dimers which enhances SERCA activity
(Blackwell et al., 2016) and potentially SERCA headpiece dynamics. I tested if observed
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Figure 21. SERCA structural dynamics in correlation with ER Ca2+ changes
(A) Addition of Iono causes an increase in ER Ca2+ content, but this increase occurs more
slowly than the second phase of the observed FRET response of 2-color SERCA. (B) 2CS
FRET does not change with addition of PBS. Data represent representative traces.
FRET fluctuations were due to changes in intermolecular FRET between two SERCA
molecules rather than representing SERCA headpiece dynamics. As expected, I detected
intermolecular FRET between Cer-SERCA and YFP-SERCA in muscle reconstituted
experimental conditions (Fig. 20A). Nevertheless, intermolecular FRET did not change in
response to spontaneous Ca2+ releases (Fig. 20B) or Iono addition (Fig. 20C). Thus, I
concluded that observed FRET changes in response to cytosolic Ca2+ elevation were a result
of genuine intramolecular structural rearrangements and not induced by SERCA
oligomerization events. More elaborate explanation on the cause of the FRET differences in
response to Ca2+ levels are provided in the discussion section.
It has been previously proposed that SERCA saturation in E2-2Ca state can occur as
a result of the inhibition by increased luminal Ca2+ (Inesi and de Meis, 1989). To test if
observed slow FRET recovery phase 2 (Fig. 16C) was due to saturation of SERCA in the E22Ca state, I monitored SERCA intramolecular FRET simultaneously with ER Ca2+ buildup
(Fig. 21A). After I detected correlated FRET decrease upon ER Ca2+ store release events, I
saturated cytosol with Ca2+ by means of Iono treatment, and observed expected biphasic
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FRET response along with a slow accumulation of Ca2+ in the ER. Ca2+ build-up in ER
occurred much more slowly that the phase 2 FRET change, which suggests that the phase 2
FRET change in Fig. 16C is not due to saturation of SERCA by luminal Ca2+ binding.
I also confirmed that the observed change in the FRET ratio or ER Ca2+ fluctuations
was not triggered by the addition of control PBS solution, which indicate that my technique
does not introduce motion artifacts that could interfere with fluorescence quantification
(Fig. 21B).
Overall, monitoring of simultaneous real-time changes in SERCA intramolecular
FRET and spontaneous Ca2+ fluctuations detected SERCA population accumulated in low
FRET state (open headpiece architecture) with increased cytosolic Ca2+ levels, while a
decrease in the cytosolic Ca2+ resulted in the redistribution of SERCA population into high
FRET state (closed headpiece conformation) (Fig. 18B). This observation was the opposite
from what I expected based on my in cells Iono experiments, where I observed a FRET
increase in response to Ca2+ elevations (Fig. 17C). Another unexpected observation was
that the defective in headpiece closure AAA-SERCA population had displayed similar to WT
anti-correlated FRET response to cytosolic Ca2+ oscillations. I propose that both of these
paradoxical to my previous observations are due SERCA accumulation in the specific slow
steps of Ca2+ transport cycle. I will elaborate in the substantial detail on both the anticorrelated FRET and Ca2+ changes and the normal AAA-SERCA FRET response to transient
Ca2+ elevation in discussion chapter.

CHAPTER FOUR
SERCA STRUCTURAL DYNAMICS IN COMPLEX WITH PLB
All-atoms MD Simulations of WT- or AAA-SERCA in the Complex with PLB
Previous MD simulations of SERCA structural dynamics predicted that the Nβ5-β6 loop was
pointing toward PLB binding cleft and in acidic loop residues Asp426, Glu429, and Glu435
were in the position to interact with various positive residues of PLB cytosolic domain
(Smolin and Robia, 2015a). Here, I investigated this possibility by performing runs and
analysis of 100 ns MD simulations of structural dynamics of WT- or AAA-SERCA complexes
with non-phosphorylated PLB or with PLB phosphorylated on Ser16 (PLBpS16). Fig. 22A
shows the starting x-ray crystal structure of SERCA-PLB complex that was used for MD
simulations: PDB accession code 4KYT (Akin et al., 2013). Since PLB cytosolic domain was
not resolved due to its dynamic structure, the cytoplasmic part of PLB from crystal
structure PDB access code 1ZLL was added (by former research assistant Dr. Nikolai
Smolin). The A-domain is highlighted in blue, N-domain is in yellow, P-domain is in black,
TM-domain is in grey, Nβ5-β6 loop is in orange, and PLB is in red. For each complex, three
independent production runs were executed.
Previously, my lab’s MD simulations of SERCA spontaneous motions detected an
increase in SERCA A-N domains separation when the triple Nβ5-β6 loop mutation was
introduced (Fig. 10). PLB association with SERCA was not able to interfere with this
specific effect of
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Figure 22. WT-SERCA and AAA-SERCA complex structural dynamics in complex with
non-phosphorylated PLB or PLB phosphorylated on Ser16
(A) SERCA-PLB starting structure 4KYT with added PLB cytosolic domain from structure
1ZLL. (B) Each panel represents distances calculated between A- and N- domains center of
mass for 3 independent trajectories for SERCA-PLB complexes. AAA-SERCA shows an increase in trajectories distribution from a starting point (red line). (C) AAA-SERCA shows
an increase in A-N domains separation compared to WT-SERCA independent of PLB phosphorylation. (D) Quantification of C. (E) Ser16 phosphorylation increases interaction with
A-domain. (F) Interaction of Nβ5-β6 loop with PLB is stable and not affected by Nβ5-β6
loop mutations or Ser16 phosphorylation. Error bars present S.D., n=3
loop mutations, and I observed a 2 Å increase in distance between centers of A- and Ndomains’ masses for AAA-SERCA compared to WT-SERCA complexes (Fig. 22C-D).
Additionally, I observed a greater deviation in distances between A- and N-domains of
individual trajectories upon triple loop mutation as detected by greater distribution of
trajectories from the starting separation distance of approximately 40 Å (Fig. 22B, red line).
This observation indicates that triple Nβ5-β6 loop mutation interferes with SERCA
cytosolic headpiece closure, and also destabilizes A- and N-domain interactions.

58
Nevertheless, phosphorylation of Ser16 did not facilitate detectable differences in distance
between A- and N-domain for either WT- or AAA-SERCA structures (Fig. 22B-D).
Considering that phosphorylation introduces negative charges to the residue with
phosphoryl group addition, and according to my structural analysis A-domain has a cluster
of positive residues (133-139) accessible for PLB binding, I hypothesized that Ser16
interaction with A-domain would be enhanced by PLB phosphorylation. As predicted,
phosphorylation increased Ser16 interaction with A-domain from 4.7±3 to 7.6±1.6 for WTSERCA and from 1.2±1.5 to 6.9±1.3 for AAA-SERCA (Fig. 22E). These results indicate that
PLB interaction with A-domain is enhanced by Ser16 phosphorylation. Additionally, I
observed a similar number of contacts between the Nβ5-β6 loop and PLB independent of
PLB phosphorylation on Ser16 or Nβ5-β6 loop mutations which indicated a stable
interaction between the Nβ5-β6 loop and PLB (Fig. 22F).
Based on the observations that PLB stably interacts with SERCA Nβ5-β6 loop and
that phosphorylated Ser16 has an increased interaction with A-domain, I further
hypothesized that PLB serves as a connecting structure between N- and A-domains via
interaction with Nβ5-β6 loop, while Ser16 phosphorylation allows more effective ‘bridging’
of A−N-domains. To further investigate this hypothesis, I extended MD simulations for WTSERCA in complex with non-phosphorylated PLB or phosphorylated on Ser16 PLBpS16
from 100 ns up to 200 ns.
Extended MD Simulations of SERCA and PLB/PLBpS16 Complexes
I started with analysis of the effect of Ser16 phosphorylation on the global structure and
dynamics of SERCA-PLB complex. I
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Figure 23. RMSD and RMSF of SERCA-PLB complex structural dynamics calculated
from MD simulations
(A) Individual SERCA domains (orange N-domain, blue A-domain, grey P-domain, and black
TM-domain) show similar global Cα RMSD fluctuations by WT-SERCA in complex with PLB
and Ser16 phosphorylated PLB. (B) RMSF analysis of SERCA Cα atoms revealed that the Aand N-domains are the most mobile, while with similar relative structural dynamics. (C)
RMSF analysis of PLB Cα atoms shows similar residue-specific fluctuations for nonphosphorylated (black) and phosphorylated on Ser16 PLB (red). Data represent mean ±S.D.
of n=3.
observed comparable global structural dynamics for SERCA in complex with PLB and
PLBpS16 by detecting similar RMSD trajectories in SERCA-domains motions (Fig. 23A) and
relatively comparable residue-specific RMSF for both complex structures, SERCA (Fig. 23B)
and PLB (Fig. 23C). It may be worth noticing that PLB Ser16 phosphorylation induced a
slight increase in motion (~1Å) for unstructured linker between cytosolic and TM-domains
(Fig. 23C, residues 20-26). This result suggests that Ser16 phosphorylation changes PLB
structural dynamics, which will be investigated in more detail below (Fig. 27, 28).
Interestingly, the amplitude of SERCA N-domain motions was reduced from the maximal of
~11 Å for SERCA alone (Fig. 8D) to a maximal of ~5 Å in complex with PLB (Fig. 23B). This
result indicates that PLB binding results in more compact conformation of SERCA
headpiece.
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Figure 24. SERCA-PLB structural dynamics in response to PLB phosphorylation on
Ser16.
(A) Number of contacts between Nβ5-β6 loop (N-loop) and PLB calculated for SERCA-PLB
(black) and SERCA-PLBpS16 (red) complexes. (B) Quantification of D. (C) Number of contacts between SERCA A-domain and PLB Ser16 residue calculated for SERCA-PLB (black)
and SERCA-PLBpS16 (red) complexes. (D) Quantification of C. (E) Number of contacts between SERCA Arg139 and PLB Ser16 residue calculated for SERCA-PLB (black) and SERCAPLBpS16 (red) complexes. (F) Number of contacts between SERCA Arg134 and PLB Ser16
residue calculated for SERCA-PLB (black) and SERCA-PLBpS16 (red) complexes. (G) Distance between SERCA A- and N-domains centers of masses calculated for SERCA-PLB
(black) and SERCA-PLBpS16 (red) complexes. (H) Quantification of G. Data represent mean
±S.D. of 3 trajectories.
Next, I confirmed that SERCA Nβ5-β6 loop interaction with PLB was still preserved
on the extended time-scale. The number of contacts between PLB and Nβ5-β6 loop was
similar with a slight increase from 17.7±6.4 to 21.3±14.3 upon Ser16 phosphorylation (Fig.
24 A-B), suggesting that PLB phosphorylation could increase interaction with Nβ5-β6 loop
on extended time-scale. I also tested to determine if my previous observation that PLB
Ser16 phosphorylation increases the number of contacts with the A-domain for the
extended time-scale. Fig. 24C shows a red trace that presents an average of three
independent trajectories for SERCA-PLBpS16 complexes above the black trace (SERCAPLB) for most of the interval of 0-100 ns. Nevertheless, at the interval of 100-200 ns
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SERCA-PLBpS16 is characterized by the decreased number of contacts compared to
SERCA-PLB (Fig. 24C), indicating an alteration of the PLB cytosolic domain position in
regard to the A-domain. This result is unexpected but not surprising, as PLB cytosolic
domain is known to be very dynamic, and extending my MD simulations is necessary to
provide more details on the PLB cytosolic domain dynamics.
Since my preceding hypothesis implied that negative charges introduced to Ser16 by
phosphorylation strengthen the interaction with SERCA A-domain positively charged
cluster (residue 133-139), I tested if the number of contacts between Ser16 and two
positive residues on A-domain surface, Arg139 and Arg134, was affected by
phosphorylated Ser16 separation from A-domain. I observed a reduction in the number of
contacts between SERCA Arg139 and PLB Ser16 from 5.8±7.6 to 0.9±1.5 upon
phosphorylation (Fig. 24E), while for Arg134 the number of contacts was below 0.2 (Fig.
24F) independent of Ser16 phosphorylation, meaning that this interaction is not likely to
occur. In Figure 24E-F I observed a large deviation in the SERCA-PLB number of contacts
measured between PLB Ser16 and Arg134 and 139. This result was most likely due to the
fact that PLB cytoplasmic domain (residues 1-23, including Ser16), is extremely dynamic
and briefly samples variety of sites on A-domain, including analyzed residues Arg134 and
Arg139, and in this way displays a great variation in the numbers of contacts it forms.
These data indicate that phosphorylation of PLB on Ser16 does not just reduce interaction
between PLB Ser16 and SERCA A-domain, but specifically with the positive cluster on the
A-domain surface.
I tested to determine if an extension of SERCA-PLB complex MD simulations
resolved the effect of PLB Ser16 phosphorylation on SERCA headpiece dynamics and
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Figure 25. PLB cytosolic domain motions are positively correlated with SERCA
headpiece structural dynamics.
Representative of n=3 covariance matrices Cα atoms for SERCA-PLB (A) and SERCAPLBpS16 (B). Covariance analysis of residue dynamics as measured from Cα revealed
positively (red) and negatively (blue) correlated motions. PLB residues are plotted after
SERCA as residues 995-1046.
calculated the number of contacts between N−A-domains for the 200 ns production runs. I
detected no difference between SERCA-PLB and SERCA-PLBpS16 complexes in A- and Ndomains separation (Fig. 24G-H). Interestingly, SERCA headpiece closure was observed as
the distance between centers of masses of A- and N-domains decreased by over 5 Å during
MD trajectories (Fig. 24G). This observation indicates SERCA spontaneous headpiece
closure in the presence of PLB, and is complementary to induction of compact headpiece
conformation which I observed as a decrease in RMSF of the most dynamic N-domain in the
presence of PLB (Fig. 8D and 23B).
Since I was not able to resolve specific effects of PLB Ser16 phosphorylation on
SERCA structural dynamics during the simulated time, I decided to test if I could identify
differences in the relative motions within the SERCA-PLB complexes by covariance

63
analysis. Fig. 25 shows representative covariance matrices for the SERCA-PLB (A) and the
SERCA-PLBpS16 (B) complexes as a residue-by-residue correlation of motions. If residues
move in the same directions, they are considered to be positively correlated (red), while
negative correlations represent motions in the opposing directions (blue). As for SERCA
alone (Fig 9D), I detected a positive self-correlation within the N-domain (residues 369603). In contrast to SERCA structure alone, the correlations within the A- and N-domains
and between A−N-domains were positive for both SERCA-PLB complexes, suggesting that
PLB association with SERCA increases dependent motions of these domains. Overall, the
covariance matrixes for SERCA in complex with PLB were presented by more red colors
(positively correlated motions) (Fig. 25) compared to SERCA alone matrix (Fig. 9D), which
indicates that PLB binding induces coordinated motions within SERCA intramolecular
interactions. Another interesting observation was the occurrence of mostly positive
correlation between the motions of PLB cytoplasmic domain (residues 1-23) and SERCA Aand N-domains for both non-phosphorylated and phosphorylated Ser16 complexes (Fig.
25), which indicates that dynamics of PLB cytoplasmic helix are coordinated with SERCA
headpiece dynamics. This conclusion is consistent with the preceding MD observation that
PLB cytosolic domain interaction with SERCA headpiece is persistent (Fig. 24B).
To summarize, my all-atom MD simulations of SERCA-PLB/PLBpS16 complexes
identified more ordered SERCA conformation induced by PLB binding as detected by the
reduction in the N-domain dynamics (Fig. 8D and 23B) and more coordinated motions of
SERCA cytoplasmic domains (Fig. 9 and 25). Additionally, I observed a stable interaction of
PLB cytosolic domain with the SERCA N5β-6β loop irrespective of Ser16 phosphorylation
(Fig. 24A-B). These data suggest that the induction of SERCA ordered conformation is due
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to the PLB coordination via SERCA N5β-6β loop. Thus, it is the PLB binding itself, not the
Ser16 phosphorylation, which regulates SERCA compact conformation and ordered
structural dynamics. I further performed MD simulations analysis targeted to resolve
effects of Ser16 on SERCA-PLB structural dynamics.
Effect of Ser16 Phosphorylation on SERCA-PLB Structural Dynamics
According to the subunit model, when SERCA inhibition by PLB is relieved by PLB
phosphorylation, PLB shifts to a new position on SERCA TM-domain (Bidwell et al., 2011;
Negash et al., 2000). Nevertheless, the precise position of phosphorylated PLB on SERCA
TM-domain after the shift is not yet determined. Therefore, I examined the change in
interaction between TM-domain of PLB and SERCA TM-domain. I calculated the number of
contacts between PLB TM-helix (Fig. 26A, red licorice structure, residues 23-52) and
SERCA M-helices that comprise the PLB docking groove (Fig. 26A, M2-helix, residues 89119, pink; M4-helix, residues 313-330, blue; M6-helix, residues 789-809, violet; M9-helix,
residues 932-950, green). I detected a slight reduction in the number of contacts between
PLB TM-helix and SERCA M2-helix from 99.2±10.8 to 88.9±8.4 upon PLB Ser16
phosphorylation. At the same time I detected an increase in the number of contacts from
52.4±5.0 to 56.8±6.6 between PLB TM-helix and SERCA M9-helix, and no change for M4and M6-helices. These data correspond to a displacement of PLB TM-domain from SERCA
M2-helix onto M9-helix. Nevertheless, the detected changes in the number of contacts are
relatively low (~10% for M2-helix and ~3% for M9-helix), and further investigations are
required to determine if the PLB TM-domain shift from the SERCA M2- to the M9-helix is a
considerable event.
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Figure 26. PLB phosphorylation on Ser16 effect on SERCA TM-domain structural dynamics.
Data represent mean ±S.D. of 3 trajectories. (A) SERCA-PLB complex structure. PLB residues used for calculations in (B) are in licorice presentation. M2-helix is pink, M4-helix is
blue, M6-helix is violet, M9-helix is green. (B) Number of contacts calculated between PLB
residues highlighted in licorice presentation in (A) and SERCA M-helices show a ~10% decrease in PLB interaction with M2-helix and a ~3% increase in contacts with M9-helix upon
PLB phosphorylation. (C) SERCA TM-domain shows gating residue Glu309 and other residues of Ca2+ transport site II in green. (D) Minimal distance between Glu309 and Ca2+
transport site II has increased upon PLB Ser16 phosphorylation by 1.14 Å.
The SERCA acidic residues Glu309, Glu770, Asp779, and Glu908 have been
identified as the Ca2+ transport site II with Glu309 being the ‘gating’ residue (Clarke et al.,
1989). A recent publication by Autry et al (Autry et al., 2016) described structural
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rearrangements in the Ca2+ transport site II induced by sarcolipin, an inhibitory peptide,
specifically emphasizing displacement of the gating residue Glu309. Since sarcolipin binds
to the same SERCA helixes as PLB, I tested to determine if PLB phosphorylation induced a
change in the transport site II gating mechanism by comparing minimal distances between
SERCA Glu309 and remaining residues of Ca2+ transport site II (residues 799, 770, and
908). I detected an increase in distance between Glu309 and transport site II from 12.6±1.0
Å to 13.3±0.2 Å upon PLB S16 phosphorylation (Fig. 26C-D), confirming distortion of the
Glu309 gating mechanism for Ca2+ transport site II upon PLB Ser16 phosphorylation. Since
the size of a Ca2+ ion is only 1.14 Å, the 0.7 Å increase in transport site may translate into
considerable structural rearrangements for Ca2+ accommodation or displacement.
I detected displacement of PLB TM-domain from SERCA M2-helix onto M9-helix and
distortion of the Glu309 gating mechanism for Ca2+ transport site II upon PLB Ser16
phosphorylation. These specific changes induced by PLB Ser16 phosphorylation indicate
that phosphorylation of PLB cytosolic domain on Ser16 has an effect on SERCA-PLB
transmembrane interactions which allow transport of Ca2+ ions. This counter-intuitive
conclusion has been suggested by several reports (Autry et al., 2016; Espinoza-Fonseca et
al., 2015a; Espinoza-Fonseca et al., 2015b; Espinoza-Fonseca and Ramirez-Salinas, 2015)
and required further investigation.
SERCA-PLB Structural Dynamics Compared to FRET in Live Cells
Previously, my lab had reported a decrease in FRET efficiency between the SERCA Nterminus and the N-terminus of PLB from 25±1.2% for non-phosphorylatable PLBSer16Ala to 14±1.3% for phosphomimetic PLB-Ser16Glu (Hou et al., 2008), which indicated
a decrease in distance between the SERCA N-terminus and the N-terminus of PLB upon PLB
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Figure 27. 200 ns MD simulations of SERCA-PLB structural dynamics compared to
FRET experiments in cells.
For B-C and E-F data represent mean ±S.D. of 3 trajectories. (A) SERCA-PLB complex
structure with SERCA N-terminus and residue 509 highlighted in red. (B) Minimal distance
between SERCA N-terminus and residue 509. (C) Quantification of C. (D) SERCA-PLB
complex structure with SERCA N-terminus and PLB N-terminus highlighted in red. (E)
Minimal distance calculated for SERCA-PLB complexes. (F) Quantification of (E) shows a
decrease between SERCA and PLB upon PLB phosphorylation on Ser16.
phosphorylation. I calculated the minimal distance between the SERCA N-terminus and the
PLB N-terminus (Fig. 27A) from MD simulations and were able to detect an average of a 4.5
Å decrease in minimal distances upon PLB phosphorylation (Fig. 27B-C). This result
suggests that while MD simulations and FRET measurements are different, these
techniques can be used to complement each other.
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I used fluorescently labeled 2-color SERCA in acceptor sensitization FRET
experiments in live cells to investigate SERCA cytosolic headpiece structural dynamics
(Gruber et al., 2014; Hou et al., 2012; Pallikkuth et al., 2013). The Cer fluorophore is
attached to N-terminus (before residue 1) while YFP is inserted before residue 509 within
A-domain (Fig. 27D). I hypothesized that I can predict in silico the structural dynamics of
SERCA headpiece upon PLB Ser16 phosphorylation, as would be detected by FRET in live
cells. I used MD generated trajectories to calculate the minimal distance between SERCA Nterminus and residue 509. Analysis of MD production runs showed no significant
separation of SERCA N-terminus and residue 509 upon PLB phosphorylation on Ser16 (Fig.
27E-F). This observation suggests that the PLBpS16 effect on SERCA structure in live cells
could be hard to resolve. On the other hand, the structural changes observed in real-time in
live cells are happening on the scale of μs and higher, and most likely further extension of
my MD runs is necessary to observe substantial SERCA structural changes in complex with
PLB that will correspond to in-cells observations.
PLB Structural Dynamics in Complex with SERCA
It has been shown that PLB phosphorylation affects PLB structure and intramolecular
interactions (Li et al., 2003; Petithory and Jencks, 1986; Sayadi and Feig, 2013; Sugita et al.,
2006). It is plausible to propose that PLB intramolecular changes induced by Ser16
phosphorylation could regulate SERCA structural dynamics to increase SERCA activity,
especially with my preceding observations that PLB phosphorylation increased SERCA Ndomain order (Fig. 9B vs. 23B) and that relative motions of A−N-domains and PLB are
correlated (Fig. 25). Thus, I set to examine some potential changes in PLB structure and
intramolecular interactions that has been proposed by numerous studies.
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Figure 28. PLB intramolecular interactions upon Ser16 phosphorylation.
For B-C and E-G data represent the mean ±S.D. of 3 trajectories. (A) SERCA-PLB complex
structure with PLB Cys24 and Tyr6 residues highlighted in violet licorice representation.
(B) Minimal distances calculated between PLB Cys24 and Tyr6 show an increase in
separation between these residues upon Ser16 phosphorylation (red). (C) Quantification of
B. (D) SERCA-PLB complex structure with PLB Ser16, Arg9, Arg13 and Arg14 highlighted in
violet licorice representation. (E-F) Minimal distance between PLB Ser16 and Arg14 (E)
and Ser16 and Arg13 (F) is reduced upon Ser16 phosphorylation (red). (G) Minimal
distance between PLB Ser16 and Arg14 is not affected by Ser16 phosphorylation (red).
PLB Ser16 phosphorylation has been reported to decrease the distance between
TM-domain residue Cys24 and cytosolic domain residue Tyr6 by 3 Å, as well as stabilize the
hinge region between PLB TM- and cytosolic domains (Li et al., 2003). Calculated minimal
distance for these residues (Fig. 28A) from my MD production runs showed 5.9 Å increase
in distance between Cys24 and Tyr6 upon Ser16 phosphorylation (Fig. 28B-C). This
contradiction may arise from the differences in physiological solutions used for FRET
experiments and current MD simulation system set-up, and stresses an importance of
complementary techniques. Nevertheless, these results implicated a separation of PLB
cytosolic domain from TM-domain upon Ser16 phosphorylation.
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Figure 29. PLB conformational changes upon Ser16 phosphorylation.
Data represent mean ±S.D. of 3 trajectories. Non-phosphorylated PLB is in black, while
SER16 phosphorylation is in red. (A) Overall PLB conformation becomes more structured
upon Ser16 phosphorylation. (B-D) α-helicity of PLB is increased (B), while unstructured
coil (B) and bent (C) arrangements are decreased upon Ser16 phosphorylation. (E) PLB
cytosolic domain α-helicity is induced by Ser16 phosphorylation. (F) Stricture of PLB and
residues used for assignment of vectors (represented by blue errors) are highlighted in
blue licorice presentation. θ represents angle between cytoplasmic and TM-domains. (G)
Angle between PLB cytoplasmic and TM-domains is increased upon Ser16 phosphorylation.
(H) Quantification of (G).

The phosphoryl group on Ser16 has been shown to interact with PLB cytosolic
residues Arg9, Arg13 and Arg14 (Fig. 28D) to unwind the cytosolic helix and affect PLB’s
inhibitory interactions with SERCA (Sugita et al., 2006). I tested to determine if Ser16
interaction with the positive arginine cluster on PLB cytosolic domain was increased with
phosphorylation by calculating minimal distances between Ser16 and each of Arg9, Arg13,
and Arg14. I observed a decrease in separation between Ser16 and neighboring Arg14 by
2.2 Å, between Ser16 and Arg13 by 0.8 Å, and no detectable changes between Ser16 and
furthermost Arg9 (Fig. 28E-G). These data confirm that the Ser16 interacts with the
cytosolic arginine cluster upon Ser16 phosphorylation, supposedly via H-bonding formed

71
by the negative phosphoryl group. Importantly, such interaction of neighboring residues
will most likely introduce a natural kink in PLB structure and result in more compact and
stabilized structural composition of PLB. I next examined PLB structural composition.
In order to investigate changes in PLB structure upon Ser16 phosphorylation, I
calculated the percentage of structured and unstructured elements. I detected an increase
from 60.0±4.5% to 65.0±4.6% in PLB overall structure as a result of Ser16 phosphorylation
(Fig. 29A). Further investigation revealed that α-helical organization was increased by from
52.0±4.0% to 56.0±3.6% (Fig. 29B), while more unstructured configurations, such as coil
and bend, were decreased by from 26.3±5.0% to 23.3±4.9% and from 10.7±1.5% to
9.3±1.5% respectively (Fig. 29C-D). Specifically, α-helicity of the cytosolic domain was
increased by from 60.9±13.1% to 77.3±6.0% upon PLB phosphorylation (Fig. 29E). Thus,
my data suggest that PLB phosphorylation on Ser16 induces more structure and order in
PLB conformation.
With PLB Ser16 phosphorylation I detected an increased separation of PLB cytosolic
and TM domains while predicating a kink in PLB domains’ linker due to phosphorylated
Ser16 increased interaction with Arg13/Arg14 cluster (Fig. 28). Such interesting structural
PLB arrangement would be possible if the kink results in twisting of PLB cytosolic domain
upward. To investigate PLB structural arrangement in more detail, I calculated the angle
between PLB cytoplasmic and TM-domains by assigning vector generated between Cα of
residues 12 and Cα of residues 4 as the cytoplasmic domain vector, while the vector of Cα
of residues 23 and Cα of residues 52 as TM-domain vector (Fig. 29F) (Sayadi and Feig,
2013). I detected a 31.6° increase in PLB intra-domain angle (Fig. 28G-H), suggesting that
PLB cytosolic domain unfolds/twists from TM-domain and obtains more upward
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conformation upon Ser16 phosphorylation. This result complements a detected increase in
minimal distance between TM residue Cys24 and cytoplasmic domain Tyr6 (Fig. 28B-C)
and confirms the presents of the kink in the Ser16 region introduced by increased
interaction between Ser16 and cytosolic Arginine cluster (Fig. 87E-F). One possible
explanation for such strange structural arrangement when the PLB cytosolic domain is
directed upwards with a kink in Ser16 region could be the preceding observation that the
PLB cytoplasmic domain strongly interacts with the SERCA Nβ5-β6 loop (Fig. 24A-B) and
thus oriented upward, toward SERCA headpiece domain.
Overall, PLB Ser16 phosphorylation has a pronounced effect on PLB structure. I
detected a separation of PLB cytosolic domain from the TM-domain by an increase in
distance (Fig. 28) and an angle (Fig. 29G-H) between these two domains. Additionally, I
observed an increase in PLB structural organization with detecting more structured and
less unstructured PLB intramolecular assemblies with Ser16 phosphorylation (Fig. 29A-E).
These results provide an alternative explanation to the question how the phosphorylation
of PLB cytosolic domain results in SERCA TM domain rearrangement to accommodate Ca2+
ions transport: detected reorganizations of PLB structural composition result in adjusted
PLB-SERCA TM interactions, which may lead to PLB shift to a distinct binding groove and
rearrange Ca2+ transport sites. I extended my studies of PLB-SERCA structural dynamics
upon PLB binding and PLB Ser16 phosphorylation in vitro.
SERCA Conformational Changes in Complex with PLB measured by FRET
To further investigate the SERCA-PLB regulatory complex, I performed an analysis of
SERCA structural conformers in vitro. Acceptor-sensitized FRET was used to examine
conformation of the SERCA cytosolic headpiece in the presence of non-phosphorylatable or
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phosphomimetic PLB. I prepared microsomal membranes from cells co-expressing WT 2color SERCA alone, SERCA with phosphomimetic PLB-Ser16Glu, and SERCA with nonphosphorylatable PLB-Ser16Ala. Fig. 30A shows FRET increase with Ca2+ concentration for
SERCA alone or in complex with PLB. The apparent Ca2+ affinity was not changed by PLB
binding as KCa was not significantly changed in PLB presence (Fig. 30B). Overall, I detected
an increase in 2-color SERCA FRET with Ca2+ concentration, and SERCA intramolecular
FRET increase was observed in complex with PLB, especially in complex with
phosphomimetic PLB-Ser16Glu. This observation indicates that phosphorylated PLB
stabilizes SERCA in the compact conformation.
SERCA conformational states were stabilized with substrates to characterize the
intermediates of the Ca2+ transport cycle (Fig. 30C-D) (MacLennan et al., 1997). As for
SERCA alone (Fig. 15B), I observed low FRET for SERCA conditions under which E2
conformers are expected to be predominant: protonated SERCA (H+), TG-bound, and E2P
phosphoenzyme intermediates (AlF4– and Vi). Higher FRET was observed for microsomes
in E1 states: ATP-bound, Ca2+-bound (2Ca), and both ATP and Ca2+-bound (2Ca+ATP)
intermediates. The FRET values for each intermediate are presented in Fig. 31. In
agreement with my previous observations (Fig. 30A), I detected higher FRET for SERCA in
complex with PLB, with the highest values attained in the presence of phosphomimetic
PLB-Ser16Glu. These data confirm that SERCA headpiece obtains very compact
conformations during high-affinity E1 states of enzymatic cycle, and, overall, the SERCA
headpiece structure obtains even more compact conformations upon PLB phosphorylation.
It has been shown that overexpression of SERCA in AAV-293 cells dramatically
enhances SERCA ability to transport Ca2+ from the cytosol, while PLB decreases SERCA
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Figure 30. SERCA structural conformers as determined by FRET in microsomes from
AAV-293 cells expressing 2-color SERCA with or without PLB.
Data represent mean ±S.E.M of at least 3 ns. (A) SERCA showed an increase in FRET with
Ca2+ concentration by itself (black) and in complex with phosphomimetic PLB-Ser16Glu
(orange), or non-phosphorylatable PLB-Ser16Ala (blue). (B) KCa remained unchanged upon
PLB binding. (C) FRET of 2-color SERCA stabilized in key enzymatic states.
mediated Ca2+ sequestering into ER (Bidwell et al., 2011). To determine the differences in
SERCA Ca2+ transport in complex with phosphomimetic or wild-type PLB, I performed Ca2+
uptake in live cells which enabled the monitoring of SERCA function as Ca2+ transient in the
presence of PLB (1 nM SERCA to 5 nM PLB transfection ratio of DNA constructs). Since PLB
phosphorylation has been shown to relieve SERCA inhibition (Simmerman et al., 1986;
Tada and Inui, 1983), I predicted that phosphomimetic PLB should have similar to or more
of overexpressed WT-SERCA phenotype in sequestering Ca2+ from cytosol. Fig. 32A shows
AAV-293 cells expressing Cer-SERCA (blue) and YFP-PLB (yellow), while the cytosolic Ca2+
is labeled with Ca2+ indicator X-Rhod-1 (red), and white arrows are indicating
untransfected (UT) cells in the same field. I triggered inositol 1,4,5-trisphosphate
receptors-mediated Ca2+ release from ER by activation of inositol 1,4,5-trisphosphate
receptors on ER membrane via stimulation of purinergic receptor with extracellular ATP
(Dubyak and el-Moatassim, 1993). Ca2+ accumulation in the cytosol was detected by an
increase in X-Rhod-1 fluorescence (Fig. 32B). I detected endogenous SERCA activity (Fig.
32B, black) as a decrease in cytosolic Ca2+ fluorescence. Subsequent application of SERCA
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inhibitor TG was designed to determine Ca2+ store remaining in ER and resulted in a rise in
Ca2+ signaling as I detected an increase in X-Rhod-1 fluorescence. Cells co-transfected with
SERCA and WT-PLB (Fig. 32B, red) displayed similar to exogenous SERCA response to ATP
and Ca2+ transport, as was expected, considering that PLB inhibits SERCA function.
Nevertheless, ER Ca2+ storage was larger than for UT cells, which suggests that SERCA
inhibited by PLB has greater than endogenous SERCA capabilities to sequester Ca2+. This
observation is contradictory to published reports, where SERCA in complex with PLB has
been shown to have similar to exogenous SERCA Ca2+ transport activity (Bidwell et al.,
2011). Even more surprising was Ca2+ transient observed for SERCA in complex with
phosphomimetic PLB-Ser16Glu/Thr17Glu (Fig. 32B, blue). Instead of expected smaller
than UT response to ATP and larger Ca2+ release from ER stores upon TG treatment, I
observed responses similar to SERCA in complex with WT-PLB, which suggests that
phosphorylation of PLB has no effect on SERCA activity in this experimental set-up. Since I
performed Ca2+ measurements in live cells, it is possible that overexpressed WT-PLB gets
phosphorylated in response to increased cytosolic Ca2+ by the cells’ endogenous PKA. To
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optimize this experiment, I would need to repeat measurements with a nonphosphorylated version of PLB-Ser16Ala, as well as determine the true ratio of PLB.
Another aspect for optimization would be determination of the in-cell SERCA: PLB ratio to
determine that enough PLB is expressed to overcome PLB pentamers formation and allow
association with SERCA (I have used up to 1 nM SERCA to 20 nM PLB ratio of constructs’
expression for FRET measurements). Overall, PLB seems to inhibit overexpressed SERCA
activity, and ER Ca2+ stores are increased for overexpressed SERCA in complex with PLB.
Our FRET structural data indicate that PLB binding to SERCA leads to SERCA
cytosolic domain compact conformation, which is further enhanced by PLB Ser16
phosphorylation (Fig. 30A). Based on the substrate-stabilized SERCA intermediates of
enzymatic cycle experiment, PLB binding and phosphorylation induce compact
conformation in all transitional states of Ca2+ transport (Fig. 30C), which suggests that
SERCA compact conformation may be of a regulatory significance. To elucidate the details
of structural aspects of SERCA regulation by PLB, further investigations are necessary. In
particular Ca2+ handling in live cells in the presence of PLB variants are of great interest, as
well as extended MD simulation of SERCA-PLB complex spontaneous dynamics.

CHAPTER FIVE
APPLICATION OF 2-COLOR FRET BIOSENSORS IN IDENTIFICATION OF REGULATORY
INTERACTIONS
Our lab has generated the 2-color SERCA FRET sensor (Hou et al., 2012) which was used in
this work, as well as in multiple assays aimed to determine SERCA structural dynamics
(Blackwell et al., 2016; Hou et al., 2012; Pallikkuth et al., 2013) and potential substrates
(Cornea et al., 2013; Gruber et al., 2014). Additionally, my lab has demonstrated that the
technique to generate 2-color FRET biosensor can be applied to other molecules. For
example, 2-color MRP-1, another transporter ATPase, was generated and used in FRET
high-throughput screening for identification of novel substrates (Iram et al., 2015). For
both SERCA and MRP-1 transporters, the most mobile domains were labeled with donor
and acceptor fluorescent proteins to monitor structural changes upon interaction with
potential modulators. The identified substrates were further tested to determine their
functional effect. Thus, my lab has developed a general technique of 2-color FRET biosensor
generation which can be applied to a wide variety of molecules. In support to this
statement, I will next describe several examples of the 2-color FRET biosensors use for
detections and investigations of regulatory interactions.
SERCA and Hax-1 Direct Interactions as Assessed by FRET
Hax-1 has been shown to interact with SERCA in vitro (Vafiadaki et al., 2009). Nevertheless,
the direct interaction of HAX-1 and SERCA in vivo has not been observed and is highly
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Figure 33. 2CS FRET in the presence of Hax-1.
2CS intramolecular FRET measured by (A) the acceptor photobleaching method (n=3,
#p≤0.0001) and (B) the acceptor sensitizing method (n=5, *p=0.008 and #p≤0.0001). Only
the acceptor sensitization assay showed a significant decrease in SERCA intramolecular
FRET in the presence of HAX1 (*). HAX1 has no additive effect on FRET decrease by TG (#).
(C) 2CS structure shows Cer fluorophore (cyan) attached to A-domain (blue), YFP
fluorophore (orange) attached to N-domain (yellow), and proposed cytoplasmic Hax-1
binding sites in red.
debated (Vandecaetsbeek et al., 2011). To observe the potential interaction in cells, I tested
to determine if Hax-1 has an effect on SERCA intramolecular FRET in AAV-293 cells
expressing unlabeled Hax-1 and 2-color SERCA (Cer fluorophore on N-terminus and YFP
before residue 509 within N-domain). I detected an apparent decrease in intramolecular
FRET for 2-color SERCA in the presence of Hax-1 using the acceptor sensitization
technique, but not the acceptor photobleaching method (Fig. 33A-B). Even though the 2color SERCA by itself showed FRET values similar to those reported previously (Hou et al.,
2012), the main concern about 2-color SERCA FRET in the presence of Hax-1 is the
possibility that the YFP fusion site on the SERCA N-domain before residue 509 can be too
close to the proposed Hax-1 binding site (Fig. 32C, loop consisting of residues E575-V594,
red) (Vafiadaki et al., 2009; Vandecaetsbeek et al., 2011). Binding of Hax-1 to this highly
accessible N-domain loop would result in Hax-1 being physically in the way of measuring
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Nevertheless, the detection of a FRET decrease in the presence of HAX-1 (Fig. 33AB) indicates direct binding of HAX-1 to SERCA, and that this interaction indeed occurs in
live cells. Following investigations are needed to determine how stable this interaction is
and if there is a functional aspect to this direct association of HAX-1 with SERCA.
Analysis of SERCA Association with DWORF
Recently identified by Dr. Eric Olson group micropeptide encoded by lncRNA DWORF has
been proposed to bind to SERCA in the same binding site as SERCA inhibitor PLB as
presented in Fig. 34A-B, thus relieving SERCA inhibition by displacement of PLB (Nelson et
al., 2016). Nevertheless, the details of SERCA-DWORF association have not been
investigated due to the fact that discovery of DWORF micropeptide is relatively recent. I
used progressive acceptor photobleaching FRET measurements to investigate DWORF
interaction with SERCA and/or PLB, as well as DWORF ability to form homo-dimers. Fig.
34C shows that DWORF-SERCA complex has lower FRET compared to PLB-SERCA complex
(Fig. 34D). The lower FRET can be explained by shorter topology of DWORF (Fig. 34A)
compared to PLB (Fig. 34B). PLB truncated all the way to TM-domain has been shown to
have decreased FRET compared to full length PLB (data by previous lab member Phil
Bidwell, not published). Plotting Cer vs. YFP resulted in a linear relationship of donor and
acceptor fluorophores (Fig. 34E) consistent with 1:1 stoichiometry. This result means that
DWORF binds to SERCA as a monomer to form a heterodimer (one Cer for one YFP
detected), the same way as PLB (Blackwell et al., 2016; Kelly et al., 2008). I detected no
FRET between DWORF-DWORF (Fig. 34F), consistent with the suggestion that DWORF is
monomeric (Nelson et al., 2016). Additionally, I did not detect FRET between DWORF-PLB
(Fig. 34G), indicating that DWORF does not form hetero-oligomers with PLB. Overall, these
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Figure 34. Analysis of DWORF homo-oligomerization and association with SERCA,
PLB and itself by acceptor photobleaching FRET.
(A) SERCA-DWORF complex shows DWORF bound to the same groove as PLB as in (B)
SERCA-PLB complex. For (C-D, F-H) photobleaching starts at the black arrow. (C) FRET
detected between Cer-SERCA and YFP-PLB. (D) FRET detected between Cer-SERCA and
YFP-DWORF. (E) Plotting Cer fluorescence as a function of YFP reveals that both the FRET
complexes, SERCA-PLB and SERCA-DWORF, are heterodimers. (F-G) No FRET detected
between Cer-DWORF and YFP-DWORF (F) or YFP-PLB (G). (H) FRET detected between
Cer-PLB and YFP-PLB represents PLB homo-oligomerization. Error bars represent SD, n=616.
data confirmed DWORF association with SERCA in 1:1 stoichiometry and showed that
DWORF most likely exists as a monomer and does not form homo- or heterodimers.
When using the acceptor sensitization FRET method, DWORF-SERCA FRET was also
decreased compared to PLB-SERCA FRET (Fig 35A-B). I observed smaller Kd of DWORF
compared to PLB (Fig. 35C), which indicates that DWORF has higher apparent affinity for
SERCA than PLB. This observation indicates that targeting PLB displacement with DWORF
overexpression can become a novel approach to enhance SERCA activity in cardiac
dysfunctions.
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Figure 35. Analysis of DWORF association with SERCA by acceptor sensitizing FRET.
(A) Representative data for FRET detected between Cer-SERCA and YFP-DWORF or YFPPLB. (B) Quantification of relative maximal FRET in (A). (C) Quantification of Kd FRET in
(A). (D) Representative data set for competing PLB off with DWORF. Ratios represent
molar ratio of PLB to DWORF DNA constructs used for transient transfection of AAV-293.
(E) Quantification of relative maximal FRET in (D). (F) Quantification of Kd in (D). Error
bars present SD, n=3.
To investigate if DWORF competes with PLB for association with SERCA, I
performed competition experiments. Specifically, I measured FRET between Cer-SERCA
and YFP-PLB in the presence of increasing DWORF expression. The maximal SERCA-to-PLB
FRET was progressively decreased by increased co-expression of DWORF (Fig. 35D-E),
which indicated that DWORF indeed competes with PLB for the same binding site. Since I
have shown that DWORF does not oligomerize with PLB (Fig. 34G), this decrease is not due
to PLB being sequestered away from SERCA into DWORF-PLB hetero-oligomeric
complexes. Additionally, I saw a progressive decrease in the apparent PLB-to-SERCA Kd
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parameter (Fig. 35F). This result indicates that PLB’s apparent affinity to SERCA increases
in the presence of DWORF. This is exactly what I would expect if PLB is competed away- a
positive correlation between an increased number of free PLB molecules and their affinity
for SERCA.
With the present FRET measurements, I still cannot exclude the possibility that
DWORF binds to SERCA at different from the PLB binding site(s) and alters SERCA-PLB
complex structure which results in a FRET decrease. Further investigations are needed to
determine the details of structural regulations of SERCA activity by DWORF.
Overall, I confirmed that DWORF binds to SERCA with higher affinity than PLB (Fig.
35C) most likely at the same binding site (Fig. 35D-E) in one to one ratio (one DWORF
molecule per one SERCA) (Fig. 34E). I showed that primarily DWORF exists as a monomer
and does not form oligomers with itself or PLB. Since DWORF positively regulates SERCA
activity (Nelson et al., 2016) and has a higher affinity to SERCA than PLB (Fig. 35C), DWORF
is very likely to become a high significance novel therapeutic target to enhance cardiac
function.
Quantification of DOX Uptake by AAV-293 Cells to Assess MRP-1 Transport Activity
2-color SERCA pump has been successfully used to identify modulators in a highthroughput screen of a library of biologically active compounds (Gruber et al., 2014). My
lab had applied the same labeling technique to generate 2-color multi-drug resistance
protein-1 (MRP-1) biosensor with GFP and TagRFP fluorophores attached to the two most
dynamic cytosolic nucleotide-binding domains, which were predicted to undergo transition
from open-to-closed conformation during extrusion of substrates from the cytosol (Aller et
al., 2009). 2-color MRP-1 FRET measurements were performed to screen for and identify
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Figure 36. DOX uptake in the nucleus of AAV-293 cells in the presence of candidate
modulators.
(A) Schematic representation of MRP-1 structure. Top panel represents high affinity for
ligands conformation with globular nucleotide-binding domains apart, while bottom panel
pictures low ligand-affinity conformation. (B) Representative images of cells treated with
DOX in the presence of candidate compound. On Ctrl image several untransfected (UT) cells
are marked with white arrows, while several MRP-1 expressing cells are marked with
green arrows. (C) Quantification of red fluorescence intensities was used as an index of
nuclei DOX accumulation. Values are ± S.E.M, normalized to UT cells in the same
microscopic field. *P < 0.0001 versus UT; #P< 0.0001 versus “Ctrl” MRP-1 alone. All error
bars represent ± S.E.M.
prospective transporter modulators (Iram et al., 2015). As a result, several MRP-1
substrates were detected: MK571 (known MRP1 inhibitor), epigallocatechin gallate
(antioxidant), mesalamine (anti-inflammatory), calcipotriol (analog of vitamin D), and
meropenem (antibiotic). To define these substrates’ functions, I tested to determine if these
compounds are able to alter MRP-1 activity.
I used doxorubicin (DOX), one of the MRP-1 substrates, to perform assessment of
MRP-1 function in the presence of the identified substrates. When DOX is not transported
out of the cell, it accumulates in the nuclei as detected by the presence of red florescence
(Fig. 36B-C, UT). Overexpressed MRP-1 prevents DOX accumulation in the nuclei and I saw
great reduction of red signal in cells nuclei (Fig. 36B-C, MRP-1). Treatment of cells with
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known MRP-1 inhibitor MK571, one of the high-throughput screening hits, resulted in DOX
accumulation in cells’ nuclei as would be expected for a transporter inhibitor. Calcipotriol
inhibited MRP-1 transport comparable to MK571 with similar DOX levels detected in cells’
nuclei (Fig. 36B-C, calcipotriol). Since calcipotriol is a vitamin D analog, this result explains
the fact that vitamin D has been demonstrated to potentiate the effect of chemotherapeutic
agents (Ma et al., 2010). Epigallocatechin gallate and meropenem exhibited no effect on
MRP-1 transport activity, even though they induced structural changes to MRP-1
organization in preceding high-throughput screening. Mesalamine interfered with DOX
redistribution in UT cells, and was not used to evaluate MRP-1 function (Fig. 36B-C,
mesalamine).
Overall, I was able to confirm two hit compounds as MRP-1 inhibitors, MK571 and
calcipotriol, which demonstrated the potential of utilizing 2-color FRET sensors in
combination of high-throughput screening analysis with functional assay in order to
identify novel modulators of protein of interest. This technique has a potential to become a
powerful tool in clinical drug discovery.

CHAPTER SIX
DISCUSSION
While SERCA is one of the major regulators of Ca2+ handling in the heart, and thus the ideal
target to improve cardiac function (Hayward et al., 2015; Inesi et al., 2008), at the moment,
no successful therapeutic approaches have been developed to increase SERCA activity. The
promising gene therapy clinical trials designed to increase SERCA expression in patients’
failing hearts have not yet achieved success in improving patients’ cardiac function (Zsebo
et al., 2014) and highlighted the apparent lack of understanding of SERCA structure and
function. One of the goals of this work was to contribute to understanding of SERCA
function via thorough investigation of SERCA structural dynamics during Ca2+ transport.
The strength of the current study was in a combination of in silico, in vitro, and ex vivo
assays that resulted in a detailed evaluation of SERCA structural and regulatory dynamics.
Structural Dynamics of WT-SERCA During Ca2+ Transport
SERCA FRET measurements in a substrates-stabilized environment allowed identification
of SERCA headpiece structural conformers for several intermediate states during Ca2+
transport (Fig. 15). I modified a Post-Alberts reaction cycle by adding my FRET data and
emphasizing states with similar intramolecular FRET efficiencies in blue boxes: SERCA
high-calcium affinity E1 states (yellow) are presented by compact conformers (~15%
FRET), while SERCA low-calcium affinity E2 states (green) have more open headpiece
conformation (~8% and ~10% FRET) during specific cycle steps (Fig. 16).
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Figure 16 presents SERCA ground protonated state E2 and biochemically equivalent
TG-bound state (E2-TG) (Satoh et al., 2011; Toyoshima et al., 2000), both of which
displayed low FRET states (~10%) suggesting SERCA open conformers. These in vitro
results were confirmed by ex vivo measurements of SERCA structural conformation in cells,
where TG also sequestered SERCA population into low FRET state (Fig. 17B). Thus, both
measurements consistently resulted in detection of low FRET.
On the other hand, SERCA biochemically-stabilized intermediate states of enzymatic
cycle representing physiological Ca2+ bound states E1-2Ca-ATP and E1P-2Ca, as well as
non-physiological state E1-2Ca, all displayed high FRET states (~15%) characterizing
SERCA closed conformers. I also detected high 2-color SERCA FRET in AAV-293 cells
treated with Iono (Fig. 17C, black). However, I observed low FRET during spontaneous Ca2+
release events (Fig. 18B). Here, I will elaborate on these apparently inconsistent
observations, which are actually the major findings of this work.
To resolve the deceptive discrepancies of the detected FRET changes in response to
intracellular Ca2+ oscillations in cells, I treated cells with Iono after detection of the
spontaneous anti-correlated FRET and cytosolic Ca2+ fluctuations (Fig. 19A). Figure 37, left
panels, shows a schematic representation of one spontaneous anti-correlated FRET/Ca2+
change and FRET biphasic response to Iono treatment. High-starting SERCA FRET (Fig.
37A, blue arrows) was observed in live cells, which are characterized by low basal Ca2+ (up
to 200 nM) and high ATP (up to 5mM). Thus, SERCA is saturated with ATP but not Ca2+ (Fig.
37A, E1-ATP), the same conditions as in non-muscle cells and in relaxed muscle cells.
I observed high SERCA FRET in microsomal preparations when both ATP and Ca2+
were high (Fig. 15B and Fig. 16, E1-2CA-ATP). However, in the cells during intracellular
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Figure 37. WT-SERCA population accumulates in states prior to slow steps during
transient Ca2+ increase.
Schematic representation of simultaneous FRET and cytosolic Ca2+ fluctuations as detected
in Fig. 19A is on the left, while corresponding transitional steps are highlighted by blue
arrows on the Post-Albers cycle (left panels). (A) In basal Ca2+, SERCA population is at
resting E1-ATP state (high FRET- open conformers) (B) During transient Ca2+ increase,
SERCA population accumulates in E2P prior to slow Pi release step (low FRET- open
conformers). I propose the existence of SERCA Ca2+-bound low FRET state (open
conformers) just before Ca2+ release event, another slow step of enzymatic cycle.
Ca2+ oscillations, I observed low FRET upon cytosolic Ca2+ increase (Fig 18B). Numerous
reports suggested that exposure to low Ca2+ shifts ATP-bound SERCA (E1-ATP) into highaffinity conformer primed for efficient Ca2+ binding and transport upon major Ca2+ influx
(Inesi et al., 2006; Jensen et al., 2006; Mintz et al., 1995). Thus, SERCA in resting E1-ATP
state is readily activated upon influx of cytosolic Ca2+. In support to this statement and in
contrast to biochemically ‘fixed’ SERCA intermediates, in live cells, where ATP levels are
high, SERCA starts cycling immediately upon Ca2+ release event. However, because of the
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slow steps in SERCA enzymatic cycle, like during release of Pi group (Champeil et al., 1986;
Hanel and Jencks, 1990; Petithory and Jencks, 1986), SERCA population accumulates in E2
low FRET state (open conformers) (Fig. 37B, E2P). These conditions occur during
contractions of cardiac or skeletal muscle cells and in non-muscle cells during intracellular
Ca2+ waves.
Ca2+ release was also identified as one of the slow steps of SERCA enzymatic cycle
(Fernandez-Belda et al., 1984). Based on this statement and the fact that I detected
accumulation of majority of pumps in low FRET state, I propose the existence of Ca2+bound state, which is most likely short-lived and exists right before Ca2+ ions are released
into ER lumen (Fig. 37B, ‘?’). After each spontaneous Ca2+ release event, probably due to
SERCA function and temporary inactivation of RyR, cytosolic Ca2+ concentration drops and
SERCA population returns to low Ca2+/high ATP conformation of high FRET state (Fig. 37A,
E1-ATP).
In contrast to transient intracellular Ca2+ increases, during sustained Ca2+ elevation
upon Iono treatment, even though SERCA population originally accumulates in high
Ca2+/high ATP low FRET state (open conformers), the majority of SERCA pumps gradually
shifts into high FRET state (compact conformers) (Fig. 17B and 19A). The immediate
decrease in phase 1 FRET upon the addition of Iono matches the prediction that the
transition of pumps to E2 conformation (Fig. 38A) is the slowest step of the Ca2+ catalytic
cycle, and the majority of SERCA pumps accumulates in E2P (or anticipated low FRET Ca2+bound) state(s).
Less clear was an increase in phase 2 FRET change observed in Iono-treated cells
(Fig. 17C). In this experiment the cytosolic Ca2+ remained high while FRET gradually
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Figure 38. WT-SERCA population accumulates in states prior to slow steps during
sustained Ca2+ increase.
Schematic representation of simultaneous FRET and cytosolic Ca2+ fluctuations as detected
in Fig. 19A is on the left, while corresponding transitional steps are highlighted by blue
arrows on the Post-Albers cycle (left panels). (A) Upon Iono treatment, phase 1 FRET
decrease (open conformers) are observed due to accumulation of WT-SERCA in E2P step of
enzymatic cycle. (B) Phase 2 FRET increase (closed conformers) of WT-SERCA during
sustained Ca2+ increase are observed due to accumulation of WT-SERCA in E1-2Ca-ADP
bound step of enzymatic cycle.
increased over a period of several minutes. This observation was surprising as I only
expected to detect phase 1 low FRET of SERCA population accumulated in the slow step of
Ca2+ release (Fig. 38A, E2P). I confirmed my observation in a muscle reconstituted setup
when Iono was applied to cells after detection of anti-correlated FRET/Ca2+ changes and
caused both the initial low FRET phase 1 and the following high FRET phase 2 (Fig. 19A). I
propose several possible explanations for the phase 2 FRET change in Iono-treated cells.
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First, Iono application as low as 2 μM has been shown to activate Ca2+/H+
exchangers and increase intracellular pH due to Ca2+ influx (Yamada et al., 1996).
Fluorescent proteins are known to be highly sensitive to pH outside of cellular levels range
(Schmitt et al., 2014). Therefore, an increase in intracellular pH (alkalinization) could affect
fluorescent proteins and result in non-relevant FRET change. Nevertheless, the experiment
with Cer-SERCA and YFP-SERCA (Fig. 20C) did not detect intermolecular FRET change
upon addition of Iono. This, it is unlikely that cell alkalinization was the direct cause of
observed phase 2 FRET change.
Second, luminal Ca2+ accumulation have been shown to inhibit SERCA in a nonactive state (Inesi and de Meis, 1989). Nevertheless, I detected slow accumulation of Ca2+ in
ER lumen after Iono treatment, much slower than phase 2 FRET change (Fig. 21A).
Therefore, I do not believe that the luminal Ca2+ may inhibit SERCA in non-active state.
Third, I cannot exclude inhibition of SERCA cycling by the ADP build-up (Inesi and
de Meis, 1989) as ADP to ATP ratio was shown to be dramatically increased upon cells
perturbation (up to 100 times) due to distortion of the mitochondrial membrane (Tantama
et al., 2013). Therefore, SERCA activation may gradually deplete ATP and increase ADP
levels in Iono-treated cells, which would shift SERCA population into non-physiological
high Ca2+/ADP bound state (Fig. 38B, E1-2Ca-ADP) which is consistent with observed high
FRET (~15%) in ligand-stabilized conformations E1-2Ca-ADP-AlF4− (Fig. 15B and 16).
To summarize, in the cells with low basal Ca2+ and high ATP levels, SERCA
accumulates in E1-ATP high FRET state (compact conformation). During temporary
cytosolic Ca2+ elevation, SERCA population progresses through E1-2Ca-ATP and
phosphoenzyme E1P-2Ca states and accumulates in the slow E2P low FRET states (open

91
conformers), which is the main and novel funding of current project. Thus, in physiological
conditions during contractions of cardiac or skeletal muscle cells, majority of the actively
cycling SERCA population has an open headpiece conformation.
Structural Dynamics of AAA-SERCA, the Nβ5-β6 Loop Mutant, During Ca2+ Transport
The experiments with AAA-SERCA, which has key residues of the Nβ5-β6 loop mutated,
allowed the understanding of the SERCA conformers’ redistribution during Ca2+ cycling in
the presence of a defective headpiece closure mechanism. Even though, I observed AAASERCA phase 1 FRET decrease after Iono application similar to WT, the subsequent
recovery and accumulation of SERCA in high FRET state was not achieved (Fig 17C and
19C). These data indicate that AAA-SERCA population was accumulating in a specific for
AAA-SERCA slow step, E2 low FRET states (open conformers), and was not able to progress
to E1 high FRET states (compact conformers) due to decreased kinetics of structural
transition from open to closed headpiece conformations (Fig. 39).
Based on these results, I was surprised to observe AAA-SERCA FRET change kinetics
similar to WT during spontaneous Ca2+ release events (Fig. 18D). I speculate that while
overexpressed AAA-SERCA has a deficit in obtaining closed conformation, endogenous
SERCA sequesters Ca2+ back into ER lumen while Na2+/Ca2+ exchangers and plasma
membrane Ca2+ ATPases remove Ca2+ from the cell, which results in cytosolic Ca2+ levels
decrease. Thus, when intracellular Ca2+ levels return to basal level, AAA-SERCA population
redistributes back to the resting E1-ATP high FRET state (Fig. 16, E1-ATP). This statement
is supported by the observed AAA-SERCA FRET decease in response to transient elevations
of Ca2+ upon RyR inhibitor Caf treatment, and following the increase in FRET as Ca2+ gets
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Figure 39. AAA-SERCA population accumulates in a new state prior to slow step
during sustained Ca2+ increase.
Schematic representation of simultaneous FRET and cytosolic Ca2+ fluctuations as detected
in Fig. 19C is on the left, while corresponding transitional steps are highlighted by blue
arrows on the Post-Albers cycle (left panels). Upon Iono treatment, AAA-SERCA population
accumulates in E2 low FRET state (open conformers) due to AAA-SERCA structural deficit
in headpiece closure, a new slow step of enzymatic cycle.
exported from the cell, supposedly via Na2+/Ca2+ exchangers and plasma membrane Ca2+
ATPases (Fig. 19D).
To summarize, when AAA-SERCA is exposed to persistent elevation of Ca2+, like
upon Iono treatment, the defective in opened-to-closed transition pumps accumulate in a
new and AAA-SERCA specific slow step, E2 low FRET states (open conformers). As a
consequence, phase 2 FRET recovery is not observed (Fig. 17C and 17C).
The Nβ5-β6 Loop as a Determinant of SERCA Structural Dynamics and Function
Previously, Dr. Nikolai Smolin had predicted that the SERCA Nβ5-β6 loop plays an
important role in SERCA headpiece transition from open-to-closed conformation (Smolin
and Robia, 2015a). Specifically, salt bridges/H-bonds between the Nβ5-β6 loop
acidic/negative residues (Asp426, Glu429, and Glu435) and basic/positive residues of the
A-domain (residues133-139) were predicted to initiate the contact between N- and A-
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domains and subsequent closure of the headpiece. The current study was designed to
investigate a role of the Nβ5-β6 loop in the SERCA dynamics during Ca2+ transport and
transporter function. To prevent the formation of the salt bridges/H-bonds between Nβ5β6 loop and the A-domain, I designed triple Alanine mutant of these three negatively
charged residues (AAA) or point mutants (Asp426Ala, Glu429Ala, and Glu435Ala).
Generated SERCA constructs were used to analyzed SERCA structure and function during
Ca2+ transport.
The all-atoms MD simulations showed that even though AAA-SERCA had conserved
overall structural integrity (Fig. 8-9), it was deficient in headpiece closure (Fig. 10) and had
reduced structural dynamics (Fig. 11). Interestingly, mutation of just one of the Nβ5-β6
loop residues was not sufficient to induce these detrimental changes; although, Glu429 may
have a more prominent role in A- and N-domains closure than other two residues (Fig.
10D). Overall, my MD simulations indicated that the Nβ5-β6 loop facilitate SERCA
structural transition to compact headpiece conformation and regulate transporter
structural dynamics.
The in silico results were confirmed by ex vivo measurements of SERCA structural
dynamics by FRET, which detected a deficit in SERCA triple loop mutant transition from
open-to-closed conformation (Fig. 17C). Again, the point loop mutants showed similar to
WT-SERCA kinetics during transition from open-to-closed conformation (Fig. 17D). Since I
detected AAA-SERCA population in a low FRET state with application of TG similar to
WT(Fig. 17B), I excluded global defects in transporter structure upon Nβ5-β6 loop
mutations and attributed AAA-SERCA deficiency in headpiece closure to a specific role of
the Nβ5-β6 loop negative residues.
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I revealed functional significance of the SERCA Nβ5-β6 loop in ATPase assay by
detecting a 63% reduction in SERCA maximal ATPase activity for AAA-SERCA compared to
WT transporter (Fig. 15A, C). Detected decline of SERCA function was not attributed to the
reduction in Ca2+ affinity as mutated transporter binds Ca2+ with similar to WT apparent
affinity (Fig. 15B). I propose that detected functional deficit in SERCA ATPase activity is a
direct consequences of AAA mutant deficit in structural transition from opened to closed
headpiece conformation.
Overall, I identified the SERCA Nβ5-β6 loop as a determinant of SERCA structural
dynamics and function by presenting evidence that the Nβ5-β6 loop facilitates closure of
SERCA headpiece and regulates ATPase activity.
Structural Dynamics of SERCA-PLB Complex
Previous MD simulation by my lab predicted that the SERCA Nβ5-β6 loop can interact with
PLB cytoplasmic domain. (Smolin and Robia, 2015a). Here I performed additional MD
simulations to confirm that interaction between the SERCA Nβ5-β6 loop and PLB was
stabilized throughout the MD trajectories and independent of loop mutations (Fig. 22F) or
PLB phosphorylation (Fig. 24A-B). Additionally, the SERCA structure was stabilized by
association with PLB as detected by reduction in RMSF N-domain (Fig. 8D vs. 23B) and in
vitro (Fig. 30), which indicates that PLB induces more compact SERCA conformation as
proposed by my lab previously (Bidwell et al., 2011). I speculate that the induction of more
ordered SERCA headpiece conformation may be a result of overall structural stabilization
by PLB. In support to this statement, I observed positive correlation between motions of
the PLB cytosolic domain and the SERCA headpiece domains (Fig. 25), as well as increase in
SERCA intramolecular motions as represented by predominantly red color (positive
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correlation) of SERCA-PLB covariance matrixes (Fig, 25) versus white color (no
correlation) of SERCA alone (Fig. 9).
Even though I did not detect a particular effect of Ser16 phosphorylation on SERCA
headpiece structural dynamics (Fig. 23 and 24G-H), I resolved structural rearrangements
within the SERCA TM-domain upon phosphorylation. Ser16 phosphorylation induced a
slight shift of PLB from the SERCA TM-helix M2 toward helix M9 (Fig. 26A-B) at the same
time as the Ca2+ transport site II was increased by displacement of gating residue Glu309
by 0.7 Å, which may be a substantial structural rearrangements to accommodate passage of
1.14 Å Ca2+ ion. This observation supports SERCA relief-of-inhibition subunit model, which
states that upon phosphorylation PLB shifts to a new position on the SERCA TM-domain
(Bidwell et al., 2011; Negash et al., 2000). Additionally, I demonstrated that like sarcolipin
(Autry et al., 2016), PLB can induce structural rearrangements in the Ca2+ transport site II
by displacement of gating residue Glu309, possibly for accommodation of Ca2+ ion passage.
Overall, these data demonstrate that phosphorylation of the cytosolic PLB domain
induces SERCA compact conformation and structural rearrangements within the SERCA
TM-domain, which most likely has functional significance for efficient Ca2+ transport.
When I examined changes within PLB itself, I detected that PLB phosphorylation
introduced a kink in the area of the phosphorylation site Ser16 (Fig. 27), increased
separation of the PLB TM- and cytosolic domains (Fig. 27 D-G), and oriented PLB more
upward (Fig. 28F-H). At the same time Ser16 phosphorylation resulted in an increase of
PLB overall structural organization (Fig. 28). I propose that these specific changes in PLB
structure are the preceding cause of changes in SERCA TM-domain. This statement is
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supported by the report that PLB phosphorylation alters structure of the SERCA-PLB
regulatory complex (Hou et al., 2008).
In summary, I propose that SERCA overall structure is stabilized by association with
PLB, and structural reorganization of PLB upon Ser16 phosphorylation results in PLB
displacement from SERCA M2- toward M9-helix. As a consequence, SERCA TM-domain Ca2+
transport site II is able to accommodate Ca2+ passage, leading to SERCA activation.
2-color ATPases as Biosensors for Identification of Regulatory Interactions
SERCA targeting in cardiac dysfunctions is aimed at increasing SERCA activity which is
predicted to improve cardiac function (Hayward et al., 2015; Inesi et al., 2008). Thus, it is
important to identify and characterize SERCA direct regulators. My lab has successfully
used the 2-color SERCA pump to investigate transporter structural dynamics, function, and
regulatory interactions (Blackwell et al., 2016; Gruber et al., 2014; Hou et al., 2012). I
utilized 2-color SERCA as a tool to investigate SERCA interactions with proposed direct
regulators of SERCA activity: HAX-1 and DWORF.
HAX-1 has been shown to directly interact with SERCA in vitro (Vafiadaki et al.,
2009), but no evidence has been reported for this interaction in vivo. My measurements
with acceptor-sensitized and acceptor photobleaching FRET in live cells detected a
decrease in FRET values in the presence of HAX-1 (Fig. 33), confirming HAX-1 direct
binding to SERCA. It is worthwhile to indicate that for the 2-color SERCA, the YFP fusion
site on the SERCA N-domain before residue 509 is too close to the proposed Hax-1 binding
site (residues E575-V594) (Vafiadaki et al., 2009; Vandecaetsbeek et al., 2011). Thus,
binding of Hax-1 to this site on the N-domain could result in Hax-1 being physically in the
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way of measuring true FRET values. Nevertheless, this detail does not disprove the
demonstrated direct interaction of HAX-1 and SERCA.
Another SERCA proposed regulator is DWORF, a recently identified micropeptide
encoded by lncRNA. It has been proposed that DWORF binds to SERCA in the same binding
groove as SERCA inhibitor PLB and relieves SERCA inhibition by displacement of PLB
(Nelson et al., 2016). I investigated the details of SERCA-DWORF regulatory interaction by
utilizing 2-color SERCA in live cell FRET measurements. I confirmed direct DWORF
interaction with SERCA (Fig. 34D) and detected a higher DWORF apparent affinity to
SERCA compared to PLB (Fig. 35C). The competition FRET experiments indicated that
DWORF competes with PLB for SERCA binding (Fig. 35A). Since I did not detect DWORFPLB oligomerization (Fig. 34G), I can exclude the possibility that PLB is sequestered into
heterodimers and the observed decrease in FRET between SERCA-PLB is due to true
competition with DWORF for a binding site. These results make DWORF a promising target
for gene therapy to enhance SERCA activity and thus improve cardiac function. I noted that
it was hard to compete PLB off with increasing DWORF levels (the decrease in maximal
FRET was not proportional to an increase in DWORF construct expressed) (Fig. 35D-E).
This observation suggests that when PLB gets competed away from SERCA and its free
concentration increases, it attains higher affinity for SERCA (Fig. 35F), which should be
taken into consideration if DWORF is to be used in gene therapy.
Utilization of 2-color SERCA FRET sensor in this work and multiple other studies is
aimed to determine SERCA structural dynamics (Blackwell et al., 2016; Hou et al., 2012;
Pallikkuth et al., 2013) and potential substrates (Cornea et al., 2013; Gruber et al., 2014). It
has been shown that the technique to generate 2-color FRET biosensor can be applied to
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other molecules. For example, 2-color MRP-1, another transporter ATPase, was generated
and used in high-throughput screening to identify potential substrates (Iram et al., 2015).
Here, I confirmed that several of the compounds identified as hits were MRP-1 modulators,
among which I recognized a novel MRP-1 inhibitor, the vitamin D analog- calcipotriol (Fig.
36). This discovery can potentially explain the mechanism of action by which vitamin D has
been demonstrated to potentiate the effect of chemotherapeutic agents (Ma et al., 2010).
In summary, 2-color FRET sensors have proved to be an effective tool in
investigation of various transporters structural dynamics, regulatory interaction,
identification of novel substrates, and analysis of ATPase function. Utilization of 2-color
FRET biosensors is a promising tool for the high-throughput screening assays that are
important in the drug discovery field (Cornea et al., 2013; Gruber et al., 2014; Iram et al.,
2015).
Clinical Implications
SERCA regulates Ca2+ handling in cardiac cells by sequestering Ca2+ from cytosol
into SR lumen, which allows heart relaxation and also restores SR Ca2+ load and determines
heart contractile force (Fig. 1) (Bers, 2006; Gwathmey et al., 1987). SERCA is an attractive
target for improving cardiac function in heart failure patients (Roe et al., 2015).
In heart failure a deficiency in SERCA levels and function has been reported
(Hasenfuss and Pieske, 2002; Hasenfuss et al., 1994). Restoration of SERCA levels in
various models of heart failure has been shown to improve cardiac performance of failing
cardiomyocytes and hearts (Kho et al., 2012). Nevertheless, latest human clinical studies
failed to significantly improve clinical outcome of heart failure patients, presumably due to
the viral delivery failure (Greenberg et al., 2016; Hayward et al., 2015). The alternative
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reason for gene therapy failure could be that solely an increase in SERCA levels is not
enough to override the regulatory processes of failing heart. Instead, enhancing SERCA
function and positive regulation are alternative strategies for improving cardiac output in
heart failure patients. Thus, it is extremely important to understand details of SERCA
function and regulation.
SERCA function and regulation have been under investigation for decades.
Nevertheless, only few SERCA specific activators have been identified so far (Cornea et al.,
2013; Dahl, 2017; Kang et al., 2016). Small molecular allosteric activators of SERCA have
been shown to increase SERCA Ca2+ transport to relive ER stress and attenuate apoptosis
and mitochondrial dysfunction (Dahl, 2017; Kang et al., 2016). However, the mechanisms of
action for SERCA pharmacological activators are still not described. Based on the FRET
method used for initial high-throughput screening in identification of these compounds
(Cornea et al., 2013; Gruber et al., 2014), I reason that binding of small-molecule activators
results in SERCA cytosolic headpiece structural rearrangement. Thus, understanding of the
SERCA structural dynamics upon binding of pharmacological activators is important for the
rational design of SERCA novel activators.
This study provided ample details of SERCA structural dynamics during Ca2+
transport cycle to enhance scientific understanding of SERCA function. Specifically, I
described SERCA structural dynamics in regard to slow steps of Ca2+ transport. Ultimately,
designing small-molecules which facilitate SERCA ‘fast’ transition through these relatively
slow steps that I described can enhance SERCA function and become beneficial for
improving cardiac function.
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Additionally, I have identified and investigated one of SERCA functional
determinant, the Nβ5-β6 loop. The Nβ5-β6 loop facilitates SERCA structural transition from
opened to closed conformations, which is one of the fundamental steps of SERCA enzymatic
cycle. I predict that enhancing SERCA cycling ‘speed’ would allow boosted Ca2+ transport
and result in improved cardiac function. Since I showed that the Nβ5-β6 loop facilitate Aand N-domains closure, I propose that a small pharmacological molecule that is designed to
interact with this loop and simultaneously serve as an extension of this structure even
further toward A-domain, could allow more efficient cytosolic headpiece closure and
enhanced cycling.
Overall, this project provided insights into SERCA structural transitions through
catalytic cycle, including identification of the SERCA novel structural and functional
determinant, the Nβ5-β6 loop. These insights contribute to understanding of SERCA
function and provide novel justifications for design of SERCA small molecular activators.
Limitations of Current Study
In present work I utilized a variety of techniques, including in silico, in vitro, and ex
vivo measurements. There are several limitations in each of these techniques that I had
encountered. For example, I performed MD simulations for SERCA spontaneous motions
for WT and mutants up to 100 ns due to limited resources of computer time available to
perform MD runs. This short timescale excludes a variety of structural changes that are
happening on a much longer timeline. Recently, MD studies of SERCA structural dynamics
as long as 1 µs were conducted (Espinoza-Fonseca et al., 2015b; Espinoza-Fonseca and
Ramirez-Salinas, 2015; Fernandez-de Gortari and Espinoza-Fonseca, 2017) and MD
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simulations at 1 µs timescale are much anticipated in scientific publications. Nevertheless, I
was able to resolve specific differences induced by loop mutations for all SERCA structures
in a short 100 ns timeline. However, I had a setback in investigation of SERCA-PLB complex
structural dynamics upon PLB Ser16 phosphorylation due to limitation of computer time
resources. Specifically, the differences detected between Ser16 and the A-domain number
of contacts for SERCA-PLB and SERCApS16 complexes at 100 ns MD simulation runs (Fig.
22E) became opposing at 200 ns (Fig. 24C). This is not surprising, considering that in
physiological conditions structural changes such as SERCA headpiece closure or Ca2+ ion
transport are predicted to take place on a µs-scale. Thus, my studies are limiting to the
detection of short-lived events and do not include the full spectrum of spontaneous
structural changes. Due to this limitation, I decided to supplement, and in this way
strengthen, my MD simulations data with physical experiments.
The basis for FRET technique have been established 70 years ago (Förster, 1948)
and up-to-date this assay plays a major role in detection and characterization of proteins’
inter- and intramolecular structural changes. The structural dynamics of 2-color SERCA
captured by acceptor photobleaching and acceptor-sensitized emission FRET
measurements have been well characterized (Bidwell et al., 2011; Hou et al., 2012; Smolin
and Robia, 2015b). Nevertheless, such measurements only capture average FRET, which
represents average conformation of SERCA population. Most likely, SERCA conformers
exist in a significant structural heterogeneity which is not detected with these methods. For
example, x-ray crystallography and electron microscopy identified only one structural state
of SERCA stabilized by TG (Takahashi et al., 2007; Toyoshima et al., 2000; Young et al.,
2001), while time-resolved fluorescence measurements showed that SERCA bound to TG
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exists in at least two conformations (Pallikkuth et al., 2013). Thus, my FRET results do not
report all the variety of SERCA conformers which presumably exists.
In this study I used muscle-like HEK-293 cell model which was initially developed
for monitoring intracellular Ca2+ oscillations (Bovo et al., 2016). This model was
supplemented with 2-color SERCA and adapted for simultaneous detection of SERCA FRET
and spontaneous Ca2+ release events. I obtained clear traces of the FRET ratio and
intracellular Ca2+ oscillations for cells expressing WT-SERCA (Fig. 18B-C. 19A-B).
Nevertheless, cells transfected with AAA-SERCA and exhibiting simultaneous FRET change
/Ca2+ release events were harder to find. Additionally, the Ca2+ fluctuations were much
rare, while traces were noisier compared to those of the cells expressing WT-SERCA (Fig.
18D, 19C-D). This difficulty of finding ‘firing’ cells limited my AAA-SERCA analysis by the
number of cells evaluated compared to WT-SERCA. On the other hand, the inability to
detect number of cells with simultaneous FRET and Ca2+ fluctuations similar to WT
indicates the deficiency of AAA-SERCA to store Ca2+ in the ER for the release event, which I
believe to be the direct consequence of AAA-SERCA deficiency in structural transitions
from open-to-closed conformation.
In my DWORF acceptor-sensitized FRET detection experiment I observed a higher
DWORF’s apparent affinity to SERCA than PLB (Fig. 35C). Nevertheless, in my competition
experiments, when I increased DWORF levels to outcompete PLB from SERCA, non-linear
SERCA-PLB FRET and Kd decreases were observed, suggesting that PLB has higher affinity
to SERCA in the presence of DWORF (Fig. 35E-F). This observation may seems as
contradictory to my previous observation that DWORF binds to SERCA better than PLB
(Fig. 35C). I believe that the increased apparent affinity of PLB to SERCA was due to the
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Figure 40. AAA-SERCA structural dynamics measured by FRET in microsomes.
(A) AAA 2-color SERCA showed steady FRET levels with Ca2+ increase. (B) FRET of AAA 2color SERCA stabilized in key enzymatic states.
increase of PLB monomers as a result of competition with DWORF. Availability of PLB
monomers enhanced PLB ability to bind to SERCA and in this way increased PLB apparent
affinity. Ideally, I need to perform the competition experiments when instead of
outcompeting PLB with DWORF from SERCA binding site, I compete DWORF from SERCA
with gradually increasing co-expression of PLB. In reality, this experiments required a large
amount of PLB DNA construct transfection, and cells, overwhelmed with DNA load, became
unhealthy, which resulted in inconstant measurements between experiments. Therefore,
optimization of the expression system is required to overcome this limitation for successful
execution of the PLB-DWORF competition experiments. One of possible strategy could be
the use of smaller DNA vectors.
Another difficulty that I encountered was the struggle to produce functional
microsomes. As presented in Figure 15, I measured WT-SERCA FRET in microsomal
membrane preparations from AAV-293 cells transiently transfected with SERCA DNA
constructs. The FRET increase curve over increasing Ca2+ levels (Fig. 15A) was regarded as
a control experiment in determination if the microsomal preparations are suitable for
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substrate-stabilized structural FRET measurements (Fig. 15B). However, for AAA-SERCA
microsomal preparations I constantly observed no significant FRET response to increasing
Ca2+ levels (Fig. 39A) or in substrate-stabilized structural measurements (Fig. 39B). Since I
prepared several batches all of which showed this result, I am unsure if AAA-SERCA
headpiece was not responsive to substrates tested, or microsomal samples were
compromised. Based on the ATPase curves, AAA-SERCA has similar to WT pump
Ca2+affinity (Fi. 14B). Thus, I believe that Ca2+ binds to mutated transporter and should
induce a structural response similar to WT. However, since AAA-SERCA has a deficit in
progression from open to closed conformer, I may only detect this specific to AAA-SERCA
slow step of enzymatic cycle. Thus, the interpretation of this experiment is ambiguous and
for that reason it was not included in the main chapter.
Overall, I believe that I was able to provide a complex review of the SERCA
structural dynamics during Ca2+ transport and identified the Nβ5-β6 loop as SERCA
structural and functional determinant by combining in silico, in vitro, and ex vivo
experiments, which were aimed at complementing and strengthening each other.
Overall Conclusion
The novel insights and substantial details of SERCA transient conformations during Ca2+
transport revealed in this study extend the scientific understanding of SERCA structural
dynamics and redistribution of SERCA conformers in response to intracellular Ca2+
fluctuations. The SERCA Nβ5-β6 loop, identified as a structural determinant of transporter
headpiece closure with a functional implication in SERCA ATPase activity and Ca2+
transport, can become a promising target of a novel small-molecule therapeutics aimed to
enhance cardiac output in heart failure patients.
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